Eventide Balanced Fund

Class A (ETAMX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$115	1.07%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Balanced Fund - with load	Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$9,425	$10,000	$10,000
Jun-2017	$10,389	$10,847	$9,969
Jun-2018	$10,405	$11,515	$9,929
Jun-2019	$11,088	$12,408	$10,710
Jun-2020	$11,872	$12,902	$11,646
Jun-2021	$15,058	$15,796	$11,607
Jun-2022	$13,621	$14,030	$10,413
Jun-2023	$14,342	$15,029	$10,315
Jun-2024	$16,127	$16,250	$10,587
Jun-2025	$17,474	$17,889	$11,230
Jun-2026	$19,976	$20,003	$11,656

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

The Fund’s equity positions and fixed income positions outperformed its broad based benchmark. The Fund’s equity positions, which are focused on high-quality dividend growth companies, outperformed fixed income during this time period. The Fund’s fixed income positions outperformed its benchmark also due to the strength of corporate bonds versus Treasury's from an allocation and selection perspective. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies, within this balanced equity and fixed income strategy, will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

Average Annual Total Returns

Table Summary
Eventide Balanced Fund - Class A
	1 Year	5 Years	10 Years
Without Load	14.32%	5.81%	7.80%
With Load	7.72%	4.57%	7.16%
Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	11.82%	4.84%	7.18%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$398,233,242
Number of Portfolio Holdings	164
Advisory Fee (net of waivers)	$2,321,098
Portfolio Turnover	34%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.3%
Other Industries	21.2%
Government Owned, No Guarantee	2.0%
Chemicals	2.0%
Machinery	2.2%
Biotech & Pharma	2.4%
Industrial Support Services	2.4%
Retail - Discretionary	2.5%
Institutional Financial Services	3.1%
Single-Family Housing	3.5%
Technology Hardware	4.1%
REIT	4.1%
Banking	4.3%
Electric Utilities	7.0%
Oil & Gas Producers	7.1%
Semiconductors	7.9%
Electrical Equipment	8.3%
Agency Fixed Rate	14.7%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.1%
Collateralized Mortgage Obligations	0.5%
Common Stocks	55.1%
Corporate Bonds	21.0%
Money Market Funds	0.0%
Municipal Bonds	4.2%
U.S. Government & Agencies	18.1%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	3.0%
nVent Electric PLC	2.9%
KLA Corporation	2.6%
Entergy Corporation	2.1%
Royalty Pharma PLC - Class A	2.1%
Targa Resources Corporation	2.1%
Dell Technologies, Inc. - Class C	2.0%
GE Vernova, Inc.	2.0%
Nasdaq, Inc.	1.6%
Williams Companies, Inc. (The)	1.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Balanced Fund - Class A (ETAMX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETAMX

Eventide Balanced Fund

Class C (ETCMX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$194	1.82%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Balanced Fund	Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$10,929	$10,847	$9,969
Jun-2018	$10,875	$11,515	$9,929
Jun-2019	$11,499	$12,408	$10,710
Jun-2020	$12,216	$12,902	$11,646
Jun-2021	$15,373	$15,796	$11,607
Jun-2022	$13,784	$14,030	$10,413
Jun-2023	$14,409	$15,029	$10,315
Jun-2024	$16,077	$16,250	$10,587
Jun-2025	$17,287	$17,889	$11,230
Jun-2026	$19,611	$20,003	$11,656

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Balanced Fund - Class C	13.44%	4.99%	6.97%
Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	11.82%	4.84%	7.18%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$398,233,242
Number of Portfolio Holdings	164
Advisory Fee (net of waivers)	$2,321,098
Portfolio Turnover	34%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.3%
Other Industries	21.2%
Government Owned, No Guarantee	2.0%
Chemicals	2.0%
Machinery	2.2%
Biotech & Pharma	2.4%
Industrial Support Services	2.4%
Retail - Discretionary	2.5%
Institutional Financial Services	3.1%
Single-Family Housing	3.5%
Technology Hardware	4.1%
REIT	4.1%
Banking	4.3%
Electric Utilities	7.0%
Oil & Gas Producers	7.1%
Semiconductors	7.9%
Electrical Equipment	8.3%
Agency Fixed Rate	14.7%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.1%
Collateralized Mortgage Obligations	0.5%
Common Stocks	55.1%
Corporate Bonds	21.0%
Money Market Funds	0.0%
Municipal Bonds	4.2%
U.S. Government & Agencies	18.1%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	3.0%
nVent Electric PLC	2.9%
KLA Corporation	2.6%
Entergy Corporation	2.1%
Royalty Pharma PLC - Class A	2.1%
Targa Resources Corporation	2.1%
Dell Technologies, Inc. - Class C	2.0%
GE Vernova, Inc.	2.0%
Nasdaq, Inc.	1.6%
Williams Companies, Inc. (The)	1.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Balanced Fund - Class C (ETCMX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCMX

Eventide Balanced Fund

Class I (ETIMX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$88	0.82%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Balanced Fund	Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$11,047	$10,847	$9,969
Jun-2018	$11,099	$11,515	$9,929
Jun-2019	$11,855	$12,408	$10,710
Jun-2020	$12,713	$12,902	$11,646
Jun-2021	$16,160	$15,796	$11,607
Jun-2022	$14,631	$14,030	$10,413
Jun-2023	$15,446	$15,029	$10,315
Jun-2024	$17,415	$16,250	$10,587
Jun-2025	$18,905	$17,889	$11,230
Jun-2026	$21,671	$20,003	$11,656

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Balanced Fund - Class I	14.64%	6.04%	8.04%
Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	11.82%	4.84%	7.18%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$398,233,242
Number of Portfolio Holdings	164
Advisory Fee (net of waivers)	$2,321,098
Portfolio Turnover	34%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.3%
Other Industries	21.2%
Government Owned, No Guarantee	2.0%
Chemicals	2.0%
Machinery	2.2%
Biotech & Pharma	2.4%
Industrial Support Services	2.4%
Retail - Discretionary	2.5%
Institutional Financial Services	3.1%
Single-Family Housing	3.5%
Technology Hardware	4.1%
REIT	4.1%
Banking	4.3%
Electric Utilities	7.0%
Oil & Gas Producers	7.1%
Semiconductors	7.9%
Electrical Equipment	8.3%
Agency Fixed Rate	14.7%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.1%
Collateralized Mortgage Obligations	0.5%
Common Stocks	55.1%
Corporate Bonds	21.0%
Money Market Funds	0.0%
Municipal Bonds	4.2%
U.S. Government & Agencies	18.1%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	3.0%
nVent Electric PLC	2.9%
KLA Corporation	2.6%
Entergy Corporation	2.1%
Royalty Pharma PLC - Class A	2.1%
Targa Resources Corporation	2.1%
Dell Technologies, Inc. - Class C	2.0%
GE Vernova, Inc.	2.0%
Nasdaq, Inc.	1.6%
Williams Companies, Inc. (The)	1.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Balanced Fund - Class I (ETIMX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIMX

Eventide Balanced Fund

Class N (ETNMX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$109	1.02%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Balanced Fund	Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$11,029	$10,847	$9,969
Jun-2018	$11,062	$11,515	$9,929
Jun-2019	$11,793	$12,408	$10,710
Jun-2020	$12,621	$12,902	$11,646
Jun-2021	$16,005	$15,796	$11,607
Jun-2022	$14,472	$14,030	$10,413
Jun-2023	$15,246	$15,029	$10,315
Jun-2024	$17,155	$16,250	$10,587
Jun-2025	$18,586	$17,889	$11,230
Jun-2026	$21,263	$20,003	$11,656

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Balanced Fund - Class N	14.40%	5.85%	7.84%
Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index	11.82%	4.84%	7.18%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$398,233,242
Number of Portfolio Holdings	164
Advisory Fee (net of waivers)	$2,321,098
Portfolio Turnover	34%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.3%
Other Industries	21.2%
Government Owned, No Guarantee	2.0%
Chemicals	2.0%
Machinery	2.2%
Biotech & Pharma	2.4%
Industrial Support Services	2.4%
Retail - Discretionary	2.5%
Institutional Financial Services	3.1%
Single-Family Housing	3.5%
Technology Hardware	4.1%
REIT	4.1%
Banking	4.3%
Electric Utilities	7.0%
Oil & Gas Producers	7.1%
Semiconductors	7.9%
Electrical Equipment	8.3%
Agency Fixed Rate	14.7%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.1%
Collateralized Mortgage Obligations	0.5%
Common Stocks	55.1%
Corporate Bonds	21.0%
Money Market Funds	0.0%
Municipal Bonds	4.2%
U.S. Government & Agencies	18.1%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	3.0%
nVent Electric PLC	2.9%
KLA Corporation	2.6%
Entergy Corporation	2.1%
Royalty Pharma PLC - Class A	2.1%
Targa Resources Corporation	2.1%
Dell Technologies, Inc. - Class C	2.0%
GE Vernova, Inc.	2.0%
Nasdaq, Inc.	1.6%
Williams Companies, Inc. (The)	1.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Balanced Fund - Class N (ETNMX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNMX

Eventide Core Bond Fund

Class A (ETARX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$76	0.74%

How did the Fund perform during the reporting period?

The Fund outperformed the benchmark for the year ended June 30, 2026. The Fund benefited from an overweight to corporate bonds and a significant underweight to Treasury bonds as corporate bonds outperformed Treasury bonds. The Fund’s investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Mortgage-backed securities and taxable municipal bonds also contributed positively to relative returns. Visit https://www.eventidefunds.com for more recent performance information.

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Core Bond Fund - with load	Bloomberg U.S. Aggregate Bond Index
Jul-2020	$9,425	$10,000
Jun-2021	$9,210	$9,820
Jun-2022	$8,113	$8,809
Jun-2023	$8,040	$8,727
Jun-2024	$8,234	$8,956
Jun-2025	$8,706	$9,500
Jun-2026	$9,071	$9,861

Fund Statistics

Table Summary
Net Assets	$215,134,089
Number of Portfolio Holdings	117
Advisory Fee (net of waivers)	$324,413
Portfolio Turnover	23%

Average Annual Total Returns

Table Summary
Eventide Core Bond Fund - Class A
	1 Year	5 Years	Since Inception (7/31/2020)
Without Load	4.19%	-0.30%	-0.65%
With Load	-1.75%	-1.47%	-1.63%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	-0.24%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.1%
Other Industries	9.6%
Institutional Financial Services	1.2%
Machinery	1.3%
Insurance	1.7%
Auto Loan	1.8%
Asset Management	2.0%
Engineering & Construction	2.3%
Retail - Discretionary	2.8%
Semiconductors	3.3%
REIT	3.7%
Government Owned, No Guarantee	4.7%
Government Sponsored	5.2%
Single-Family Housing	5.3%
Oil & Gas Producers	6.1%
Banking	6.5%
Electric Utilities	9.5%
Agency Fixed Rate	30.9%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.8%
Corporate Bonds	50.0%
Municipal Bonds	6.5%
U.S. Government & Agencies	41.7%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Ginnie Mae II Pool, 5.000%, due 04/20/56	1.5%
Ginnie Mae II Pool, 4.500%, due 11/20/55	1.4%
Ginnie Mae II Pool, 4.500%, due 03/20/54	1.4%
Fannie Mae Pool, 4.500%, due 11/1/52	1.3%
Ginnie Mae II Pool, 4.000%, due 03/20/56	1.3%
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.3%
Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32	1.3%
Fannie Mae Pool, 4.000%, due 12/1/40	1.3%
Federal National Mortgage Association, 5.625%, due 07/15/37	1.3%
Fannie Mae Pool, 4.000%, due 08/1/52	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2025. For more complete information, you may review the Fund’s November 1, 2025 prospectus, which is available at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Effective September 1, 2025, the Advisor reduced the expense limitation by 0.10%.

Eventide Core Bond Fund - Class A (ETARX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETARX

Eventide Core Bond Fund

Class C (ETCRX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$151	1.49%

How did the Fund perform during the reporting period?

The Fund outperformed the benchmark for the year ended June 30, 2026. The Class underperformed for the same period due to class specific fees. The Fund benefited from an overweight to corporate bonds and a significant underweight to Treasury bonds as corporate bonds outperformed Treasury bonds. The Fund’s investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Mortgage-backed securities and taxable municipal bonds also contributed positively to relative returns. Visit https://www.eventidefunds.com for more recent performance information.

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Core Bond Fund	Bloomberg U.S. Aggregate Bond Index
Jul-2020	$10,000	$10,000
Jun-2021	$9,698	$9,820
Jun-2022	$8,499	$8,809
Jun-2023	$8,357	$8,727
Jun-2024	$8,485	$8,956
Jun-2025	$8,913	$9,500
Jun-2026	$9,208	$9,861

Fund Statistics

Table Summary
Net Assets	$215,134,089
Number of Portfolio Holdings	117
Advisory Fee (net of waivers)	$324,413
Portfolio Turnover	23%

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (7/31/2020)
Eventide Core Bond Fund - Class C	3.32%	-1.03%	-1.38%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	-0.24%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.1%
Other Industries	9.6%
Institutional Financial Services	1.2%
Machinery	1.3%
Insurance	1.7%
Auto Loan	1.8%
Asset Management	2.0%
Engineering & Construction	2.3%
Retail - Discretionary	2.8%
Semiconductors	3.3%
REIT	3.7%
Government Owned, No Guarantee	4.7%
Government Sponsored	5.2%
Single-Family Housing	5.3%
Oil & Gas Producers	6.1%
Banking	6.5%
Electric Utilities	9.5%
Agency Fixed Rate	30.9%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.8%
Corporate Bonds	50.0%
Municipal Bonds	6.5%
U.S. Government & Agencies	41.7%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Ginnie Mae II Pool, 5.000%, due 04/20/56	1.5%
Ginnie Mae II Pool, 4.500%, due 11/20/55	1.4%
Ginnie Mae II Pool, 4.500%, due 03/20/54	1.4%
Fannie Mae Pool, 4.500%, due 11/1/52	1.3%
Ginnie Mae II Pool, 4.000%, due 03/20/56	1.3%
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.3%
Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32	1.3%
Fannie Mae Pool, 4.000%, due 12/1/40	1.3%
Federal National Mortgage Association, 5.625%, due 07/15/37	1.3%
Fannie Mae Pool, 4.000%, due 08/1/52	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Core Bond Fund - Class C (ETCRX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCRX

Eventide Core Bond Fund

Class I (ETIRX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$51	0.49%

How did the Fund perform during the reporting period?

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Core Bond Fund	Bloomberg U.S. Aggregate Bond Index
Jul-2020	$10,000	$10,000
Jun-2021	$9,776	$9,820
Jun-2022	$8,651	$8,809
Jun-2023	$8,593	$8,727
Jun-2024	$8,812	$8,956
Jun-2025	$9,353	$9,500
Jun-2026	$9,755	$9,861

Fund Statistics

Table Summary
Net Assets	$215,134,089
Number of Portfolio Holdings	117
Advisory Fee (net of waivers)	$324,413
Portfolio Turnover	23%

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (7/31/2020)
Eventide Core Bond Fund - Class I	4.30%	-0.04%	-0.42%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	-0.24%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.1%
Other Industries	9.6%
Institutional Financial Services	1.2%
Machinery	1.3%
Insurance	1.7%
Auto Loan	1.8%
Asset Management	2.0%
Engineering & Construction	2.3%
Retail - Discretionary	2.8%
Semiconductors	3.3%
REIT	3.7%
Government Owned, No Guarantee	4.7%
Government Sponsored	5.2%
Single-Family Housing	5.3%
Oil & Gas Producers	6.1%
Banking	6.5%
Electric Utilities	9.5%
Agency Fixed Rate	30.9%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.8%
Corporate Bonds	50.0%
Municipal Bonds	6.5%
U.S. Government & Agencies	41.7%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Ginnie Mae II Pool, 5.000%, due 04/20/56	1.5%
Ginnie Mae II Pool, 4.500%, due 11/20/55	1.4%
Ginnie Mae II Pool, 4.500%, due 03/20/54	1.4%
Fannie Mae Pool, 4.500%, due 11/1/52	1.3%
Ginnie Mae II Pool, 4.000%, due 03/20/56	1.3%
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.3%
Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32	1.3%
Fannie Mae Pool, 4.000%, due 12/1/40	1.3%
Federal National Mortgage Association, 5.625%, due 07/15/37	1.3%
Fannie Mae Pool, 4.000%, due 08/1/52	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Core Bond Fund - Class I (ETIRX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIRX

Eventide Core Bond Fund

Class N (ETNRX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$70	0.69%

How did the Fund perform during the reporting period?

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Core Bond Fund	Bloomberg U.S. Aggregate Bond Index
Jul-2020	$10,000	$10,000
Jun-2021	$9,761	$9,820
Jun-2022	$8,620	$8,809
Jun-2023	$8,543	$8,727
Jun-2024	$8,743	$8,956
Jun-2025	$9,262	$9,500
Jun-2026	$9,641	$9,861

Fund Statistics

Table Summary
Net Assets	$215,134,089
Number of Portfolio Holdings	117
Advisory Fee (net of waivers)	$324,413
Portfolio Turnover	23%

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (7/31/2020)
Eventide Core Bond Fund - Class N	4.10%	-0.25%	-0.62%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	-0.24%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.1%
Other Industries	9.6%
Institutional Financial Services	1.2%
Machinery	1.3%
Insurance	1.7%
Auto Loan	1.8%
Asset Management	2.0%
Engineering & Construction	2.3%
Retail - Discretionary	2.8%
Semiconductors	3.3%
REIT	3.7%
Government Owned, No Guarantee	4.7%
Government Sponsored	5.2%
Single-Family Housing	5.3%
Oil & Gas Producers	6.1%
Banking	6.5%
Electric Utilities	9.5%
Agency Fixed Rate	30.9%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	1.8%
Corporate Bonds	50.0%
Municipal Bonds	6.5%
U.S. Government & Agencies	41.7%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Ginnie Mae II Pool, 5.000%, due 04/20/56	1.5%
Ginnie Mae II Pool, 4.500%, due 11/20/55	1.4%
Ginnie Mae II Pool, 4.500%, due 03/20/54	1.4%
Fannie Mae Pool, 4.500%, due 11/1/52	1.3%
Ginnie Mae II Pool, 4.000%, due 03/20/56	1.3%
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.3%
Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32	1.3%
Fannie Mae Pool, 4.000%, due 12/1/40	1.3%
Federal National Mortgage Association, 5.625%, due 07/15/37	1.3%
Fannie Mae Pool, 4.000%, due 08/1/52	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Core Bond Fund - Class N (ETNRX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNRX

Eventide Dividend Growth Fund

Class A (ETADX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$134	1.20%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Chart showing performance over last 10 years or since inception

Table Summary
	Eventide Dividend Growth Fund - with load	Bloomberg US Mid Cap Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Sep-2017	$9,425	$10,000	$10,000
Jun-2018	$9,236	$10,897	$11,146
Jun-2019	$10,081	$11,723	$10,713
Jun-2020	$10,742	$11,654	$10,166
Jun-2021	$15,814	$17,332	$17,109
Jun-2022	$13,778	$14,753	$12,770
Jun-2023	$15,250	$16,886	$14,093
Jun-2024	$18,505	$18,980	$15,045
Jun-2025	$20,362	$21,448	$16,516
Jun-2026	$25,029	$25,785	$22,734

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

The Fund underperformed the broad based benchmark for the year. The high-quality, dividend-focused style of the Fund did not keep up with the higher-beta constituents of the equal-weighted broad based benchmark during a very strong year for US equities from an absolute return perspective. An underweight to Healthcare and an overweight to Utilities was a drag on relative returns while an intentional underweight to Consumer Staples was a positive. From a stock selection standpoint, strength in Information Technology holdings was more than offset by weakness in Financials, Healthcare and Consumer Discretionary positions. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

Average Annual Total Returns

Table Summary
Eventide Dividend Growth Fund - Class A
	1 Year	5 Years	Since Inception (9/29/2017)
Without Load	22.92%	9.62%	11.81%
With Load	15.88%	8.32%	11.05%
Bloomberg US Mid Cap Total Return Index	20.22%	8.27%	11.43%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	9.84%

Fund Statistics

Net Assets$1,425,327,971
Number of Portfolio Holdings59
Advisory Fee (with fee recapture)$9,119,479
Portfolio Turnover42%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.7%
Other Industries	13.6%
Banking	2.0%
Transportation & Logistics	2.2%
Oil & Gas Services & Equipment	2.8%
Biotech & Pharma	3.0%
Commercial Support Services	3.3%
Retail - Discretionary	3.4%
Industrial Support Services	3.6%
Medical Equipment & Devices	3.9%
Chemicals	4.0%
Institutional Financial Services	4.3%
Industrial REITs	5.0%
Technology Hardware	6.8%
Electric Utilities	8.0%
Oil & Gas Producers	8.5%
Semiconductors	11.1%
Electrical Equipment	12.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	100.0%
Money Market Funds	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	4.9%
nVent Electric PLC	4.7%
KLA Corporation	4.4%
Entergy Corporation	3.6%
Targa Resources Corporation	3.5%
GE Vernova, Inc.	3.2%
Dell Technologies, Inc. - Class C	3.1%
Royalty Pharma PLC - Class A	3.0%
Element Solutions, Inc.	2.9%
Nasdaq, Inc.	2.7%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Dividend Growth Fund - Class A (ETADX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( https://www.eventidefunds.com ), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETADX

Eventide Dividend Growth Fund

Class C (ETCDX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$216	1.95%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Dividend Growth Fund	Bloomberg US Mid Cap Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Sep-2017	$10,000	$10,000	$10,000
Jun-2018	$9,763	$10,897	$11,146
Jun-2019	$10,577	$11,723	$10,713
Jun-2020	$11,188	$11,654	$10,166
Jun-2021	$16,326	$17,332	$17,109
Jun-2022	$14,110	$14,753	$12,770
Jun-2023	$15,490	$16,886	$14,093
Jun-2024	$18,665	$18,980	$15,045
Jun-2025	$20,359	$21,448	$16,516
Jun-2026	$24,862	$25,785	$22,734

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (9/29/2017)
Eventide Dividend Growth Fund - Class C	22.12%	8.77%	10.97%
Bloomberg US Mid Cap Total Return Index	20.22%	8.27%	11.43%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	9.84%

Fund Statistics

Net Assets$1,425,327,971
Number of Portfolio Holdings59
Advisory Fee (with fee recapture)$9,119,479
Portfolio Turnover42%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.7%
Other Industries	13.6%
Banking	2.0%
Transportation & Logistics	2.2%
Oil & Gas Services & Equipment	2.8%
Biotech & Pharma	3.0%
Commercial Support Services	3.3%
Retail - Discretionary	3.4%
Industrial Support Services	3.6%
Medical Equipment & Devices	3.9%
Chemicals	4.0%
Institutional Financial Services	4.3%
Industrial REITs	5.0%
Technology Hardware	6.8%
Electric Utilities	8.0%
Oil & Gas Producers	8.5%
Semiconductors	11.1%
Electrical Equipment	12.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	100.0%
Money Market Funds	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	4.9%
nVent Electric PLC	4.7%
KLA Corporation	4.4%
Entergy Corporation	3.6%
Targa Resources Corporation	3.5%
GE Vernova, Inc.	3.2%
Dell Technologies, Inc. - Class C	3.1%
Royalty Pharma PLC - Class A	3.0%
Element Solutions, Inc.	2.9%
Nasdaq, Inc.	2.7%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Dividend Growth Fund - Class C (ETCDX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( https://www.eventidefunds.com ), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCDX

Eventide Dividend Growth Fund

Class I (ETIDX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$106	0.95%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Dividend Growth Fund	Bloomberg US Mid Cap Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Sep-2017	$10,000	$10,000	$10,000
Jun-2018	$9,832	$10,897	$11,146
Jun-2019	$10,756	$11,723	$10,713
Jun-2020	$11,487	$11,654	$10,166
Jun-2021	$16,942	$17,332	$17,109
Jun-2022	$14,787	$14,753	$12,770
Jun-2023	$16,395	$16,886	$14,093
Jun-2024	$19,952	$18,980	$15,045
Jun-2025	$22,006	$21,448	$16,516
Jun-2026	$27,114	$25,785	$22,734

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (9/29/2017)
Eventide Dividend Growth Fund - Class I	23.21%	9.86%	12.07%
Bloomberg US Mid Cap Total Return Index	20.22%	8.27%	11.43%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	9.84%

Fund Statistics

Net Assets$1,425,327,971
Number of Portfolio Holdings59
Advisory Fee (with fee recapture)$9,119,479
Portfolio Turnover42%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.7%
Other Industries	13.6%
Banking	2.0%
Transportation & Logistics	2.2%
Oil & Gas Services & Equipment	2.8%
Biotech & Pharma	3.0%
Commercial Support Services	3.3%
Retail - Discretionary	3.4%
Industrial Support Services	3.6%
Medical Equipment & Devices	3.9%
Chemicals	4.0%
Institutional Financial Services	4.3%
Industrial REITs	5.0%
Technology Hardware	6.8%
Electric Utilities	8.0%
Oil & Gas Producers	8.5%
Semiconductors	11.1%
Electrical Equipment	12.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	100.0%
Money Market Funds	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	4.9%
nVent Electric PLC	4.7%
KLA Corporation	4.4%
Entergy Corporation	3.6%
Targa Resources Corporation	3.5%
GE Vernova, Inc.	3.2%
Dell Technologies, Inc. - Class C	3.1%
Royalty Pharma PLC - Class A	3.0%
Element Solutions, Inc.	2.9%
Nasdaq, Inc.	2.7%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Dividend Growth Fund - Class I (ETIDX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( https://www.eventidefunds.com ), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIDX

Eventide Dividend Growth Fund

Class N (ETNDX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$128	1.15%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Dividend Growth Fund	Bloomberg US Mid Cap Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Sep-2017	$10,000	$10,000	$10,000
Jun-2018	$9,813	$10,897	$11,146
Jun-2019	$10,716	$11,723	$10,713
Jun-2020	$11,424	$11,654	$10,166
Jun-2021	$16,817	$17,332	$17,109
Jun-2022	$14,647	$14,753	$12,770
Jun-2023	$16,209	$16,886	$14,093
Jun-2024	$19,678	$18,980	$15,045
Jun-2025	$21,662	$21,448	$16,516
Jun-2026	$26,631	$25,785	$22,734

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (9/29/2017)
Eventide Dividend Growth Fund - Class N	22.94%	9.63%	11.84%
Bloomberg US Mid Cap Total Return Index	20.22%	8.27%	11.43%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	9.84%

Fund Statistics

Net Assets$1,425,327,971
Number of Portfolio Holdings59
Advisory Fee (with fee recapture)$9,119,479
Portfolio Turnover42%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	1.7%
Other Industries	13.6%
Banking	2.0%
Transportation & Logistics	2.2%
Oil & Gas Services & Equipment	2.8%
Biotech & Pharma	3.0%
Commercial Support Services	3.3%
Retail - Discretionary	3.4%
Industrial Support Services	3.6%
Medical Equipment & Devices	3.9%
Chemicals	4.0%
Institutional Financial Services	4.3%
Industrial REITs	5.0%
Technology Hardware	6.8%
Electric Utilities	8.0%
Oil & Gas Producers	8.5%
Semiconductors	11.1%
Electrical Equipment	12.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	100.0%
Money Market Funds	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Trane Technologies PLC	4.9%
nVent Electric PLC	4.7%
KLA Corporation	4.4%
Entergy Corporation	3.6%
Targa Resources Corporation	3.5%
GE Vernova, Inc.	3.2%
Dell Technologies, Inc. - Class C	3.1%
Royalty Pharma PLC - Class A	3.0%
Element Solutions, Inc.	2.9%
Nasdaq, Inc.	2.7%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Dividend Growth Fund - Class N (ETNDX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( https://www.eventidefunds.com ), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNDX

Eventide Exponential Technologies Fund

Class A (ETAEX)

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$192	1.61%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Exponential Technologies Fund - with load	Bloomberg US 2500 Technology Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2020	$9,425	$10,000	$10,000
Jun-2021	$18,002	$15,123	$16,831
Jun-2022	$10,451	$10,750	$12,562
Jun-2023	$11,474	$12,666	$13,864
Jun-2024	$11,436	$13,833	$14,800
Jun-2025	$12,870	$15,995	$16,247
Jun-2026	$17,871	$26,242	$22,364

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

The Fund outperformed the benchmark during the period. This was due primarily to outperformance in the Industrial and IT sectors which overcame a slight drag from the Consumer Services and Financial sectors. The fiscal year exhibited many of the same trends that have persisted over the past two years, the most important being the size of the Artificial Intelligence ("AI") opportunity and outperformance of companies that help facilitate AI in realizing its potential. We also observed that small- and mid-cap began to stabilize and outperform compared to large and mega cap. We believe that a disciplined approach to positioning is well-suited to deliver long- term value across market cycles, while still enabling participation in themes of technological innovation driving human progress. Visit https://www.eventidefunds.com for more recent performance information.

Average Annual Total Returns

Table Summary
Eventide Exponential Technologies Fund - Class A
	1 Year	5 Years	Since Inception (6/30/2020)
Without Load	38.86%	-0.15%	11.25%
With Load	30.88%	-1.32%	10.16%
Bloomberg US 2500 Technology Total Return Index	64.06%	11.65%	17.44%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	14.36%

Fund Statistics

Table Summary
Net Assets	$105,759,930
Number of Portfolio Holdings	54
Advisory Fee (net of waivers)	$847,825
Portfolio Turnover	125%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	5.9%
Asset Management	0.7%
Aerospace & Defense	1.8%
Technology Services	2.6%
Industrial Intermediate Prod	2.9%
Money Market Funds	3.1%
Oil & Gas Services & Equipment	3.9%
Biotech & Pharma	4.3%
Electrical Equipment	5.6%
Technology Hardware	9.6%
Software	10.2%
Medical Equipment & Devices	10.6%
Semiconductors	38.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	96.0%
Corporate Bonds	0.7%
Money Market Funds	3.3%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Micron Technology, Inc.	6.5%
NVIDIA Corporation	5.3%
Guardant Health, Inc.	5.1%
Advanced Micro Devices, Inc.	4.8%
Lam Research Corporation	4.0%
Arista Networks, Inc.	3.2%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.0%
Generac Holdings, Inc.	3.0%
Xometry, Inc. - Class A	2.9%
Toast, Inc. - Class A	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2025. For more complete information, you may review the Fund’s November 1, 2025 prospectus which is available at

https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Effective September 1, 2025, the Advisor lowered the Fund’s advisory fee by 0.15% to 0.95% and reduced the expense limitation by 0.08%.

Eventide Exponential Technologies Fund - Class A (ETAEX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETAEX

Eventide Exponential Technologies Fund

Class C (ETCEX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$281	2.36%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Exponential Technologies Fund	Bloomberg US 2500 Technology Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2020	$10,000	$10,000	$10,000
Jun-2021	$18,980	$15,123	$16,831
Jun-2022	$10,928	$10,750	$12,562
Jun-2023	$11,912	$12,666	$13,864
Jun-2024	$11,780	$13,833	$14,800
Jun-2025	$13,150	$15,995	$16,247
Jun-2026	$18,121	$26,242	$22,364

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (6/30/2020)
Eventide Exponential Technologies Fund - Class C	37.81%	-0.92%	10.42%
Bloomberg US 2500 Technology Total Return Index	64.06%	11.65%	17.44%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	14.36%

Fund Statistics

Table Summary
Net Assets	$105,759,930
Number of Portfolio Holdings	54
Advisory Fee (net of waivers)	$847,825
Portfolio Turnover	125%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	5.9%
Asset Management	0.7%
Aerospace & Defense	1.8%
Technology Services	2.6%
Industrial Intermediate Prod	2.9%
Money Market Funds	3.1%
Oil & Gas Services & Equipment	3.9%
Biotech & Pharma	4.3%
Electrical Equipment	5.6%
Technology Hardware	9.6%
Software	10.2%
Medical Equipment & Devices	10.6%
Semiconductors	38.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	96.0%
Corporate Bonds	0.7%
Money Market Funds	3.3%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Micron Technology, Inc.	6.5%
NVIDIA Corporation	5.3%
Guardant Health, Inc.	5.1%
Advanced Micro Devices, Inc.	4.8%
Lam Research Corporation	4.0%
Arista Networks, Inc.	3.2%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.0%
Generac Holdings, Inc.	3.0%
Xometry, Inc. - Class A	2.9%
Toast, Inc. - Class A	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2025. For more complete information, you may review the Fund’s November 1, 2025 prospectus which is available at

Eventide Exponential Technologies Fund - Class C (ETCEX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCEX

Eventide Exponential Technologies Fund

Class I (ETIEX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$163	1.36%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Exponential Technologies Fund	Bloomberg US 2500 Technology Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2020	$10,000	$10,000	$10,000
Jun-2021	$19,140	$15,123	$16,831
Jun-2022	$11,128	$10,750	$12,562
Jun-2023	$12,254	$12,666	$13,864
Jun-2024	$12,244	$13,833	$14,800
Jun-2025	$13,817	$15,995	$16,247
Jun-2026	$19,224	$26,242	$22,364

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (6/30/2020)
Eventide Exponential Technologies Fund - Class I	39.13%	0.09%	11.51%
Bloomberg US 2500 Technology Total Return Index	64.06%	11.65%	17.44%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	14.36%

Fund Statistics

Table Summary
Net Assets	$105,759,930
Number of Portfolio Holdings	54
Advisory Fee (net of waivers)	$847,825
Portfolio Turnover	125%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	5.9%
Asset Management	0.7%
Aerospace & Defense	1.8%
Technology Services	2.6%
Industrial Intermediate Prod	2.9%
Money Market Funds	3.1%
Oil & Gas Services & Equipment	3.9%
Biotech & Pharma	4.3%
Electrical Equipment	5.6%
Technology Hardware	9.6%
Software	10.2%
Medical Equipment & Devices	10.6%
Semiconductors	38.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	96.0%
Corporate Bonds	0.7%
Money Market Funds	3.3%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Micron Technology, Inc.	6.5%
NVIDIA Corporation	5.3%
Guardant Health, Inc.	5.1%
Advanced Micro Devices, Inc.	4.8%
Lam Research Corporation	4.0%
Arista Networks, Inc.	3.2%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.0%
Generac Holdings, Inc.	3.0%
Xometry, Inc. - Class A	2.9%
Toast, Inc. - Class A	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2025. For more complete information, you may review the Fund’s November 1, 2025 prospectus which is available at

Eventide Exponential Technologies Fund - Class I (ETIEX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIEX

Eventide Exponential Technologies Fund

Class N (ETNEX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$186	1.56%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Exponential Technologies Fund	Bloomberg US 2500 Technology Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2020	$10,000	$10,000	$10,000
Jun-2021	$19,100	$15,123	$16,831
Jun-2022	$11,078	$10,750	$12,562
Jun-2023	$12,174	$12,666	$13,864
Jun-2024	$12,143	$13,833	$14,800
Jun-2025	$13,665	$15,995	$16,247
Jun-2026	$18,981	$26,242	$22,364

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (6/30/2020)
Eventide Exponential Technologies Fund - Class N	38.90%	-0.12%	11.27%
Bloomberg US 2500 Technology Total Return Index	64.06%	11.65%	17.44%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	14.36%

Fund Statistics

Table Summary
Net Assets	$105,759,930
Number of Portfolio Holdings	54
Advisory Fee (net of waivers)	$847,825
Portfolio Turnover	125%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	5.9%
Asset Management	0.7%
Aerospace & Defense	1.8%
Technology Services	2.6%
Industrial Intermediate Prod	2.9%
Money Market Funds	3.1%
Oil & Gas Services & Equipment	3.9%
Biotech & Pharma	4.3%
Electrical Equipment	5.6%
Technology Hardware	9.6%
Software	10.2%
Medical Equipment & Devices	10.6%
Semiconductors	38.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	96.0%
Corporate Bonds	0.7%
Money Market Funds	3.3%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Micron Technology, Inc.	6.5%
NVIDIA Corporation	5.3%
Guardant Health, Inc.	5.1%
Advanced Micro Devices, Inc.	4.8%
Lam Research Corporation	4.0%
Arista Networks, Inc.	3.2%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.0%
Generac Holdings, Inc.	3.0%
Xometry, Inc. - Class A	2.9%
Toast, Inc. - Class A	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2025. For more complete information, you may review the Fund’s November 1, 2025 prospectus which is available at

Eventide Exponential Technologies Fund - Class N (ETNEX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNEX

Eventide Gilead Fund

Class A (ETAGX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$169	1.41%

How did the Fund perform during the reporting period?

The Fund outperformed the benchmark during the fiscal year. This outperformance was due to both allocation and selection. Industrials exposure, favoring domestic manufacturing and global power, and Healthcare, with an overweight in biotech, generated the most sector outperformance. Financials and Communication Services, with significant underweights in the Fund relative to the benchmark, were the sectors that contributed the most to underperformance. The Fund’s investment strategy remains anchored in the belief that companies with sustainable competitive advantages in attractive industries run by great management teams that focus on value creation for their stakeholders generate superior long-term risk-adjusted returns. Visit https://www.eventidefunds.com for more recent performance information.

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Gilead Fund - with load	Bloomberg US Mid Cap Growth Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$9,426	$10,000	$10,000
Jun-2017	$12,082	$11,502	$12,472
Jun-2018	$15,222	$13,310	$14,658
Jun-2019	$17,713	$14,972	$14,088
Jun-2020	$20,650	$16,364	$13,369
Jun-2021	$30,848	$23,619	$22,500
Jun-2022	$20,769	$18,357	$16,794
Jun-2023	$24,036	$21,567	$18,534
Jun-2024	$23,876	$24,128	$19,785
Jun-2025	$27,113	$28,084	$21,720
Jun-2026	$37,851	$32,690	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

Average Annual Total Returns

Table Summary
Eventide Gilead Fund - Class A
	1 Year	5 Years	10 Years
Without Load	39.60%	4.18%	14.91%
With Load	31.58%	2.95%	14.24%
Bloomberg US Mid Cap Growth Total Return Index	16.40%	6.72%	12.57%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$3,438,647,827
Number of Portfolio Holdings	76
Advisory Fee	$28,902,794
Portfolio Turnover	16%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	4.9%
Other Industries	6.5%
Oil & Gas Services & Equipment	1.1%
Construction Materials	1.4%
Technology Hardware	1.8%
Retail - Discretionary	2.0%
Electric Utilities	2.1%
Oil & Gas Producers	2.4%
Transportation & Logistics	2.5%
Technology Services	2.8%
Engineering & Construction	3.2%
Industrial Support Services	5.3%
Industrial Intermediate Prod	5.9%
Software	7.1%
Electrical Equipment	9.1%
Medical Equipment & Devices	11.4%
Biotech & Pharma	12.4%
Semiconductors	18.1%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	98.6%
Contingent Value Rights	0.1%
Corporate Bonds	1.1%
Money Market Funds	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Lam Research Corporation	6.5%
Xometry, Inc. - Class A	5.9%
Guardant Health, Inc.	5.5%
ASML Holding N.V.	3.8%
Trane Technologies PLC	2.7%
Lattice Semiconductor Corporation	2.6%
United Rentals, Inc.	2.6%
Datadog, Inc. - Class A	2.5%
Generac Holdings, Inc.	2.5%
Old Dominion Freight Line, Inc.	2.5%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Gilead Fund - Class A (ETAGX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETAGX

Eventide Gilead Fund

Class C (ETCGX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$258	2.16%

How did the Fund perform during the reporting period?

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Gilead Fund	Bloomberg US Mid Cap Growth Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,724	$11,502	$12,472
Jun-2018	$15,910	$13,310	$14,658
Jun-2019	$18,376	$14,972	$14,088
Jun-2020	$21,263	$16,364	$13,369
Jun-2021	$31,517	$23,619	$22,500
Jun-2022	$21,051	$18,357	$16,794
Jun-2023	$24,182	$21,567	$18,534
Jun-2024	$23,845	$24,128	$19,785
Jun-2025	$26,873	$28,084	$21,720
Jun-2026	$37,232	$32,690	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Gilead Fund - Class C	38.55%	3.39%	14.05%
Bloomberg US Mid Cap Growth Total Return Index	16.40%	6.72%	12.57%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$3,438,647,827
Number of Portfolio Holdings	76
Advisory Fee	$28,902,794
Portfolio Turnover	16%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	4.9%
Other Industries	6.5%
Oil & Gas Services & Equipment	1.1%
Construction Materials	1.4%
Technology Hardware	1.8%
Retail - Discretionary	2.0%
Electric Utilities	2.1%
Oil & Gas Producers	2.4%
Transportation & Logistics	2.5%
Technology Services	2.8%
Engineering & Construction	3.2%
Industrial Support Services	5.3%
Industrial Intermediate Prod	5.9%
Software	7.1%
Electrical Equipment	9.1%
Medical Equipment & Devices	11.4%
Biotech & Pharma	12.4%
Semiconductors	18.1%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	98.6%
Contingent Value Rights	0.1%
Corporate Bonds	1.1%
Money Market Funds	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Lam Research Corporation	6.5%
Xometry, Inc. - Class A	5.9%
Guardant Health, Inc.	5.5%
ASML Holding N.V.	3.8%
Trane Technologies PLC	2.7%
Lattice Semiconductor Corporation	2.6%
United Rentals, Inc.	2.6%
Datadog, Inc. - Class A	2.5%
Generac Holdings, Inc.	2.5%
Old Dominion Freight Line, Inc.	2.5%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Gilead Fund - Class C (ETCGX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCGX

Eventide Gilead Fund

Class I (ETILX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$139	1.16%

How did the Fund perform during the reporting period?

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Gilead Fund	Bloomberg US Mid Cap Growth Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,850	$11,502	$12,472
Jun-2018	$16,233	$13,310	$14,658
Jun-2019	$18,938	$14,972	$14,088
Jun-2020	$22,128	$16,364	$13,369
Jun-2021	$33,138	$23,619	$22,500
Jun-2022	$22,360	$18,357	$16,794
Jun-2023	$25,938	$21,567	$18,534
Jun-2024	$25,834	$24,128	$19,785
Jun-2025	$29,409	$28,084	$21,720
Jun-2026	$41,156	$32,690	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Gilead Fund - Class I	39.95%	4.43%	15.20%
Bloomberg US Mid Cap Growth Total Return Index	16.40%	6.72%	12.57%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$3,438,647,827
Number of Portfolio Holdings	76
Advisory Fee	$28,902,794
Portfolio Turnover	16%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	4.9%
Other Industries	6.5%
Oil & Gas Services & Equipment	1.1%
Construction Materials	1.4%
Technology Hardware	1.8%
Retail - Discretionary	2.0%
Electric Utilities	2.1%
Oil & Gas Producers	2.4%
Transportation & Logistics	2.5%
Technology Services	2.8%
Engineering & Construction	3.2%
Industrial Support Services	5.3%
Industrial Intermediate Prod	5.9%
Software	7.1%
Electrical Equipment	9.1%
Medical Equipment & Devices	11.4%
Biotech & Pharma	12.4%
Semiconductors	18.1%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	98.6%
Contingent Value Rights	0.1%
Corporate Bonds	1.1%
Money Market Funds	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Lam Research Corporation	6.5%
Xometry, Inc. - Class A	5.9%
Guardant Health, Inc.	5.5%
ASML Holding N.V.	3.8%
Trane Technologies PLC	2.7%
Lattice Semiconductor Corporation	2.6%
United Rentals, Inc.	2.6%
Datadog, Inc. - Class A	2.5%
Generac Holdings, Inc.	2.5%
Old Dominion Freight Line, Inc.	2.5%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Gilead Fund - Class I (ETILX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETILX

Eventide Gilead Fund

Class N (ETGLX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$163	1.36%

How did the Fund perform during the reporting period?

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Gilead Fund	Bloomberg US Mid Cap Growth Total Return Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,827	$11,502	$12,472
Jun-2018	$16,168	$13,310	$14,658
Jun-2019	$18,820	$14,972	$14,088
Jun-2020	$21,955	$16,364	$13,369
Jun-2021	$32,807	$23,619	$22,500
Jun-2022	$22,095	$18,357	$16,794
Jun-2023	$25,580	$21,567	$18,534
Jun-2024	$25,421	$24,128	$19,785
Jun-2025	$28,886	$28,084	$21,720
Jun-2026	$40,342	$32,690	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Gilead Fund - Class N	39.66%	4.22%	14.97%
Bloomberg US Mid Cap Growth Total Return Index	16.40%	6.72%	12.57%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$3,438,647,827
Number of Portfolio Holdings	76
Advisory Fee	$28,902,794
Portfolio Turnover	16%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	4.9%
Other Industries	6.5%
Oil & Gas Services & Equipment	1.1%
Construction Materials	1.4%
Technology Hardware	1.8%
Retail - Discretionary	2.0%
Electric Utilities	2.1%
Oil & Gas Producers	2.4%
Transportation & Logistics	2.5%
Technology Services	2.8%
Engineering & Construction	3.2%
Industrial Support Services	5.3%
Industrial Intermediate Prod	5.9%
Software	7.1%
Electrical Equipment	9.1%
Medical Equipment & Devices	11.4%
Biotech & Pharma	12.4%
Semiconductors	18.1%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	98.6%
Contingent Value Rights	0.1%
Corporate Bonds	1.1%
Money Market Funds	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Lam Research Corporation	6.5%
Xometry, Inc. - Class A	5.9%
Guardant Health, Inc.	5.5%
ASML Holding N.V.	3.8%
Trane Technologies PLC	2.7%
Lattice Semiconductor Corporation	2.6%
United Rentals, Inc.	2.6%
Datadog, Inc. - Class A	2.5%
Generac Holdings, Inc.	2.5%
Old Dominion Freight Line, Inc.	2.5%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Gilead Fund - Class N (ETGLX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETGLX

Eventide Healthcare & Life Sciences Fund

Class A (ETAHX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$209	1.54%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Healthcare & Life Sciences Fund - with load	S&P Biotechnology Select Industry Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$9,424	$10,000	$10,000
Jun-2017	$11,789	$14,299	$12,472
Jun-2018	$17,545	$17,676	$14,658
Jun-2019	$19,409	$16,320	$14,088
Jun-2020	$24,196	$20,841	$13,369
Jun-2021	$26,683	$25,257	$22,500
Jun-2022	$17,111	$13,856	$16,794
Jun-2023	$23,736	$15,537	$18,534
Jun-2024	$21,415	$17,391	$19,785
Jun-2025	$21,344	$15,589	$21,720
Jun-2026	$36,563	$29,931	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

During the fiscal year, the Fund significantly outperformed the broader market. This was largely due to the outperformance of the biotech industry. After several years of struggling, biotech drew significant investor interest because of its high innovation, attractiveness as a source of M&A targets, favorable regulatory dynamics, and a differentiated correlation profile. The Fund has remained overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit https://www.eventidefunds.com for more recent performance information.

Average Annual Total Returns

Table Summary
Eventide Healthcare & Life Sciences Fund - Class A
	1 Year	5 Years	10 Years
Without Load	71.30%	6.50%	14.52%
With Load	61.45%	5.25%	13.84%
S&P Biotechnology Select Industry Index	92.00%	3.45%	11.59%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$1,789,380,256
Number of Portfolio Holdings	90
Advisory Fee	$16,626,771
Portfolio Turnover	87%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	3.1%
Health Care Facilities & Services	0.8%
Money Market Funds	1.1%
Software	2.0%
Medical Equipment & Devices	14.8%
Biotech & Pharma	78.2%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	97.0%
Contingent Value Rights	0.4%
Convertible Bonds	0.0%
Money Market Funds	1.1%
Private Investments	1.3%
Warrant	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Guardant Health, Inc.	5.4%
Mirum Pharmaceuticals, Inc.	3.5%
Kymera Therapeutics, Inc.	3.2%
Abivax S.A. - ADR	2.9%
BeLite Bio Inc	2.8%
Trevi Therapeutics, Inc.	2.8%
MBX Biosciences, Inc.	2.7%
Vaxcyte, Inc.	2.7%
Cytokinetics, Inc.	2.7%
Argenx S.E. - ADR	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Healthcare & Life Sciences Fund - Class A (ETAHX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETAHX

Eventide Healthcare & Life Sciences Fund

Class C (ETCHX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$309	2.29%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Healthcare & Life Sciences Fund	S&P Biotechnology Select Industry Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,415	$14,299	$12,472
Jun-2018	$18,334	$17,676	$14,658
Jun-2019	$20,137	$16,320	$14,088
Jun-2020	$24,916	$20,841	$13,369
Jun-2021	$27,270	$25,257	$22,500
Jun-2022	$17,349	$13,856	$16,794
Jun-2023	$23,892	$15,537	$18,534
Jun-2024	$21,398	$17,391	$19,785
Jun-2025	$21,164	$15,589	$21,720
Jun-2026	$35,983	$29,931	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class C	70.02%	5.70%	13.66%
S&P Biotechnology Select Industry Index	92.00%	3.45%	11.59%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$1,789,380,256
Number of Portfolio Holdings	90
Advisory Fee	$16,626,771
Portfolio Turnover	87%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	3.1%
Health Care Facilities & Services	0.8%
Money Market Funds	1.1%
Software	2.0%
Medical Equipment & Devices	14.8%
Biotech & Pharma	78.2%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	97.0%
Contingent Value Rights	0.4%
Convertible Bonds	0.0%
Money Market Funds	1.1%
Private Investments	1.3%
Warrant	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Guardant Health, Inc.	5.4%
Mirum Pharmaceuticals, Inc.	3.5%
Kymera Therapeutics, Inc.	3.2%
Abivax S.A. - ADR	2.9%
BeLite Bio Inc	2.8%
Trevi Therapeutics, Inc.	2.8%
MBX Biosciences, Inc.	2.7%
Vaxcyte, Inc.	2.7%
Cytokinetics, Inc.	2.7%
Argenx S.E. - ADR	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Healthcare & Life Sciences Fund - Class C (ETCHX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCHX

Eventide Healthcare & Life Sciences Fund

Class I (ETIHX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$175	1.29%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Healthcare & Life Sciences Fund	S&P Biotechnology Select Industry Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,540	$14,299	$12,472
Jun-2018	$18,760	$17,676	$14,658
Jun-2019	$20,772	$16,320	$14,088
Jun-2020	$25,960	$20,841	$13,369
Jun-2021	$28,697	$25,257	$22,500
Jun-2022	$18,442	$13,856	$16,794
Jun-2023	$25,656	$15,537	$18,534
Jun-2024	$23,199	$17,391	$19,785
Jun-2025	$23,179	$15,589	$21,720
Jun-2026	$39,811	$29,931	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class I	71.76%	6.77%	14.82%
S&P Biotechnology Select Industry Index	92.00%	3.45%	11.59%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$1,789,380,256
Number of Portfolio Holdings	90
Advisory Fee	$16,626,771
Portfolio Turnover	87%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	3.1%
Health Care Facilities & Services	0.8%
Money Market Funds	1.1%
Software	2.0%
Medical Equipment & Devices	14.8%
Biotech & Pharma	78.2%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	97.0%
Contingent Value Rights	0.4%
Convertible Bonds	0.0%
Money Market Funds	1.1%
Private Investments	1.3%
Warrant	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Guardant Health, Inc.	5.4%
Mirum Pharmaceuticals, Inc.	3.5%
Kymera Therapeutics, Inc.	3.2%
Abivax S.A. - ADR	2.9%
BeLite Bio Inc	2.8%
Trevi Therapeutics, Inc.	2.8%
MBX Biosciences, Inc.	2.7%
Vaxcyte, Inc.	2.7%
Cytokinetics, Inc.	2.7%
Argenx S.E. - ADR	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Healthcare & Life Sciences Fund - Class I (ETIHX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIHX

Eventide Healthcare & Life Sciences Fund

Class N (ETNHX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$202	1.49%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Healthcare & Life Sciences Fund	S&P Biotechnology Select Industry Index	Bloomberg US 3000 Equal Weight Total Return Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$12,519	$14,299	$12,472
Jun-2018	$18,687	$17,676	$14,658
Jun-2019	$20,652	$16,320	$14,088
Jun-2020	$25,749	$20,841	$13,369
Jun-2021	$28,411	$25,257	$22,500
Jun-2022	$18,226	$13,856	$16,794
Jun-2023	$25,302	$15,537	$18,534
Jun-2024	$22,833	$17,391	$19,785
Jun-2025	$22,772	$15,589	$21,720
Jun-2026	$39,023	$29,931	$29,898

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class N	71.36%	6.55%	14.59%
S&P Biotechnology Select Industry Index	92.00%	3.45%	11.59%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

Fund Statistics

Table Summary
Net Assets	$1,789,380,256
Number of Portfolio Holdings	90
Advisory Fee	$16,626,771
Portfolio Turnover	87%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	3.1%
Health Care Facilities & Services	0.8%
Money Market Funds	1.1%
Software	2.0%
Medical Equipment & Devices	14.8%
Biotech & Pharma	78.2%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Common Stocks	97.0%
Contingent Value Rights	0.4%
Convertible Bonds	0.0%
Money Market Funds	1.1%
Private Investments	1.3%
Warrant	0.2%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
Guardant Health, Inc.	5.4%
Mirum Pharmaceuticals, Inc.	3.5%
Kymera Therapeutics, Inc.	3.2%
Abivax S.A. - ADR	2.9%
BeLite Bio Inc	2.8%
Trevi Therapeutics, Inc.	2.8%
MBX Biosciences, Inc.	2.7%
Vaxcyte, Inc.	2.7%
Cytokinetics, Inc.	2.7%
Argenx S.E. - ADR	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Healthcare & Life Sciences Fund - Class N (ETNHX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNHX

Eventide Large Cap Focus Fund

Class A (ETLAX)

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$130	1.19%

How did the Fund perform during the reporting period?

The Fund’s underperformance in Financials, Materials, Utilities, Information Technology, and Healthcare was partly offset by outperformance in Industrials, Consumer Staples, and Real Estate. The Fund outperformed in the first half of calendar 2026 due to strong stock selection, particularly within Industrials and Information Technology. We remain focused on the Fund owning companies that create significant value for their stakeholders, while also trading at attractive valuations. Visit https://www.eventidefunds.com for more recent performance information.

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Large Cap Focus Fund - with load	S&P 500^® Index
Jun-2022	$9,425	$10,000
Jun-2023	$10,769	$11,959
Jun-2024	$13,183	$14,896
Jun-2025	$14,768	$17,155
Jun-2026	$17,383	$20,985

Fund Statistics

Table Summary
Net Assets	$204,740,418
Number of Portfolio Holdings	51
Advisory Fee (net of waivers)	$974,701
Portfolio Turnover	30%

Average Annual Total Returns

Table Summary
Eventide Large Cap Focus Fund - Class A
	1 Year	Since Inception (6/30/2022)
Without Load	17.71%	16.54%
With Load	10.96%	14.82%
S&P 500^® Index	22.32%	20.36%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.9%
Other Industries	3.0%
Institutional Financial Services	1.2%
Technology Services	1.5%
Banking	1.6%
Oil & Gas Producers	2.4%
Industrial Support Services	2.5%
Transportation & Logistics	3.0%
Specialty Finance	3.3%
Medical Equipment & Devices	3.9%
Chemicals	5.2%
Software	5.6%
Retail - Discretionary	6.5%
Biotech & Pharma	6.6%
Electric Utilities	7.5%
Technology Hardware	7.6%
Electrical Equipment	10.4%
Semiconductors	25.3%

Market Cap Weighting

Table Summary
Value	Value
Large Cap	70.8%
Mid Cap	26.2%
Cash/Other	3.0%
Small Cap	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
NVIDIA Corporation	6.3%
GE Vernova, Inc.	6.0%
Broadcom, Inc.	4.8%
Trane Technologies PLC	4.4%
Linde PLC	4.3%
Royalty Pharma PLC - Class A	4.1%
Dell Technologies, Inc. - Class C	3.5%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.3%
American Express Company	3.3%
KLA Corporation	3.3%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Large Cap Focus Fund - Class A (ETLAX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETLAX

Eventide Large Cap Focus Fund

Class C (ETLCX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$210	1.94%

How did the Fund perform during the reporting period?

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Large Cap Focus Fund	S&P 500^® Index
Jun-2022	$10,000	$10,000
Jun-2023	$11,360	$11,959
Jun-2024	$13,790	$14,896
Jun-2025	$15,340	$17,155
Jun-2026	$17,926	$20,985

Fund Statistics

Table Summary
Net Assets	$204,740,418
Number of Portfolio Holdings	51
Advisory Fee (net of waivers)	$974,701
Portfolio Turnover	30%

Average Annual Total Returns

Table Summary
	1 Year	Since Inception (6/30/2022)
Eventide Large Cap Focus Fund - Class C	16.85%	15.71%
S&P 500^® Index	22.32%	20.36%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.9%
Other Industries	3.0%
Institutional Financial Services	1.2%
Technology Services	1.5%
Banking	1.6%
Oil & Gas Producers	2.4%
Industrial Support Services	2.5%
Transportation & Logistics	3.0%
Specialty Finance	3.3%
Medical Equipment & Devices	3.9%
Chemicals	5.2%
Software	5.6%
Retail - Discretionary	6.5%
Biotech & Pharma	6.6%
Electric Utilities	7.5%
Technology Hardware	7.6%
Electrical Equipment	10.4%
Semiconductors	25.3%

Market Cap Weighting

Table Summary
Value	Value
Large Cap	70.8%
Mid Cap	26.2%
Cash/Other	3.0%
Small Cap	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
NVIDIA Corporation	6.3%
GE Vernova, Inc.	6.0%
Broadcom, Inc.	4.8%
Trane Technologies PLC	4.4%
Linde PLC	4.3%
Royalty Pharma PLC - Class A	4.1%
Dell Technologies, Inc. - Class C	3.5%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.3%
American Express Company	3.3%
KLA Corporation	3.3%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Large Cap Focus Fund - Class C (ETLCX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETLCX

Eventide Large Cap Focus Fund

Class I (ETLIX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$102	0.94%

How did the Fund perform during the reporting period?

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Large Cap Focus Fund	S&P 500^® Index
Jun-2022	$10,000	$10,000
Jun-2023	$11,455	$11,959
Jun-2024	$14,058	$14,896
Jun-2025	$15,789	$17,155
Jun-2026	$18,632	$20,985

Fund Statistics

Table Summary
Net Assets	$204,740,418
Number of Portfolio Holdings	51
Advisory Fee (net of waivers)	$974,701
Portfolio Turnover	30%

Average Annual Total Returns

Table Summary
	1 Year	Since Inception (6/30/2022)
Eventide Large Cap Focus Fund - Class I	18.01%	16.83%
S&P 500^® Index	22.32%	20.36%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.9%
Other Industries	3.0%
Institutional Financial Services	1.2%
Technology Services	1.5%
Banking	1.6%
Oil & Gas Producers	2.4%
Industrial Support Services	2.5%
Transportation & Logistics	3.0%
Specialty Finance	3.3%
Medical Equipment & Devices	3.9%
Chemicals	5.2%
Software	5.6%
Retail - Discretionary	6.5%
Biotech & Pharma	6.6%
Electric Utilities	7.5%
Technology Hardware	7.6%
Electrical Equipment	10.4%
Semiconductors	25.3%

Market Cap Weighting

Table Summary
Value	Value
Large Cap	70.8%
Mid Cap	26.2%
Cash/Other	3.0%
Small Cap	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
NVIDIA Corporation	6.3%
GE Vernova, Inc.	6.0%
Broadcom, Inc.	4.8%
Trane Technologies PLC	4.4%
Linde PLC	4.3%
Royalty Pharma PLC - Class A	4.1%
Dell Technologies, Inc. - Class C	3.5%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.3%
American Express Company	3.3%
KLA Corporation	3.3%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Large Cap Focus Fund - Class I (ETLIX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETLIX

Eventide Large Cap Focus Fund

Class N (ETLNX)

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$124	1.14%

How did the Fund perform during the reporting period?

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Large Cap Focus Fund	S&P 500^® Index
Jun-2022	$10,000	$10,000
Jun-2023	$11,443	$11,959
Jun-2024	$14,014	$14,896
Jun-2025	$15,708	$17,155
Jun-2026	$18,494	$20,985

Fund Statistics

Table Summary
Net Assets	$204,740,418
Number of Portfolio Holdings	51
Advisory Fee (net of waivers)	$974,701
Portfolio Turnover	30%

Average Annual Total Returns

Table Summary
	1 Year	Since Inception (6/30/2022)
Eventide Large Cap Focus Fund - Class N	17.74%	16.62%
S&P 500^® Index	22.32%	20.36%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.9%
Other Industries	3.0%
Institutional Financial Services	1.2%
Technology Services	1.5%
Banking	1.6%
Oil & Gas Producers	2.4%
Industrial Support Services	2.5%
Transportation & Logistics	3.0%
Specialty Finance	3.3%
Medical Equipment & Devices	3.9%
Chemicals	5.2%
Software	5.6%
Retail - Discretionary	6.5%
Biotech & Pharma	6.6%
Electric Utilities	7.5%
Technology Hardware	7.6%
Electrical Equipment	10.4%
Semiconductors	25.3%

Market Cap Weighting

Table Summary
Value	Value
Large Cap	70.8%
Mid Cap	26.2%
Cash/Other	3.0%
Small Cap	0.0%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
NVIDIA Corporation	6.3%
GE Vernova, Inc.	6.0%
Broadcom, Inc.	4.8%
Trane Technologies PLC	4.4%
Linde PLC	4.3%
Royalty Pharma PLC - Class A	4.1%
Dell Technologies, Inc. - Class C	3.5%
Taiwan Semiconductor Manufacturing Company Ltd. - ADR	3.3%
American Express Company	3.3%
KLA Corporation	3.3%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.

Eventide Large Cap Focus Fund - Class N (ETLNX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETLNX

Eventide Limited-Term Bond Fund

Class A (ETABX )

Annual Shareholder Report - June 30, 2026

Fund Overview

This annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class A	$73	0.72%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Limited-Term Bond Fund - with load	Bloomberg U.S. 1-5 Year Government/Credit Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$9,422	$10,000	$10,000
Jun-2017	$9,472	$10,011	$9,969
Jun-2018	$9,424	$9,991	$9,929
Jun-2019	$9,860	$10,525	$10,710
Jun-2020	$10,284	$11,096	$11,646
Jun-2021	$10,330	$11,140	$11,607
Jun-2022	$9,689	$10,561	$10,413
Jun-2023	$9,799	$10,581	$10,315
Jun-2024	$10,298	$11,074	$10,587
Jun-2025	$10,899	$11,785	$11,230
Jun-2026	$11,249	$12,139	$11,656

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

The Fund’s performance for the year ended June 30, 2026, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to Treasury's. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to Treasury bonds as corporate bonds outperformed Treasury bonds. The portfolio’s significantly shorter duration profile relative to the benchmark captured yield change gains as rates rose across the curve, but the carry deficit from holding shorter-dated instruments and the underweight to the long end of the curve produced a net yield drag that detracted from relative returns. Visit https://www.eventidefunds.com for more recent performance information.

Average Annual Total Returns

Table Summary
Eventide Limited-Term Bond Fund - Class A
	1 Year	5 Years	10 Years
Without Load	3.21%	1.72%	1.79%
With Load	-2.75%	0.52%	1.18%
Bloomberg U.S. 1-5 Year Government/Credit Index	3.00%	1.73%	1.96%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$218,186,572
Number of Portfolio Holdings	116
Advisory Fee (net of waivers)	$365,974
Portfolio Turnover	11%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.6%
Other Industries	14.6%
Construction Materials	2.0%
Asset Management	2.0%
Electrical Equipment	2.2%
Insurance	2.3%
Engineering & Construction	2.4%
Machinery	3.2%
Semiconductors	3.2%
Single-Family Housing	3.5%
Retail - Discretionary	5.5%
REIT	5.6%
Oil & Gas Producers	6.1%
Government Sponsored	6.2%
Electric Utilities	7.2%
Government Owned, No Guarantee	8.0%
Banking	9.6%
Agency Fixed Rate	13.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	2.0%
Corporate Bonds	65.1%
Municipal Bonds	4.1%
U.S. Government & Agencies	28.8%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.6%
Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31	1.4%
Duke Energy Florida, LLC, 2.500%, due 12/1/29	1.4%
Federal National Mortgage Association, 7.125%, due 01/15/30	1.4%
Federal Home Loan Mortgage Corporation, 4.125%, due 02/20/31	1.4%
Truist Financial Corporation, 5.071%, due 05/20/31	1.3%
Home Depot, Inc. (The), 4.750%, due 06/25/29	1.3%
Royal Bank of Canada, 1.150%, due 07/14/26	1.3%
Federal National Mortgage Association, 6.625%, due 11/15/30	1.3%
Freddie Mac Pool, 4.500%, due 01/1/41	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Limited-Term Bond Fund - Class A (ETABX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETABX

Eventide Limited-Term Bond Fund

Class C (ETCBX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class C	$149	1.47%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Limited-Term Bond Fund	Bloomberg U.S. 1-5 Year Government/Credit Index	Bloomberg U.S. Aggregate Bond Index
Dec-2018	$10,000	$10,000	$10,000
Jun-2019	$10,424	$10,427	$10,708
Jun-2020	$10,789	$10,993	$11,644
Jun-2021	$10,749	$11,037	$11,605
Jun-2022	$10,003	$10,463	$10,411
Jun-2023	$10,052	$10,483	$10,313
Jun-2024	$10,481	$10,971	$10,585
Jun-2025	$11,015	$11,676	$11,228
Jun-2026	$11,287	$12,026	$11,653

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (12/14/2018)
Eventide Limited-Term Bond Fund - Class C	2.47%	0.98%	1.62%
Bloomberg U.S. 1-5 Year Government/Credit Index	3.00%	1.73%	2.48%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	2.05%

Fund Statistics

Table Summary
Net Assets	$218,186,572
Number of Portfolio Holdings	116
Advisory Fee (net of waivers)	$365,974
Portfolio Turnover	11%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.6%
Other Industries	14.6%
Construction Materials	2.0%
Asset Management	2.0%
Electrical Equipment	2.2%
Insurance	2.3%
Engineering & Construction	2.4%
Machinery	3.2%
Semiconductors	3.2%
Single-Family Housing	3.5%
Retail - Discretionary	5.5%
REIT	5.6%
Oil & Gas Producers	6.1%
Government Sponsored	6.2%
Electric Utilities	7.2%
Government Owned, No Guarantee	8.0%
Banking	9.6%
Agency Fixed Rate	13.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	2.0%
Corporate Bonds	65.1%
Municipal Bonds	4.1%
U.S. Government & Agencies	28.8%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.6%
Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31	1.4%
Duke Energy Florida, LLC, 2.500%, due 12/1/29	1.4%
Federal National Mortgage Association, 7.125%, due 01/15/30	1.4%
Federal Home Loan Mortgage Corporation, 4.125%, due 02/20/31	1.4%
Truist Financial Corporation, 5.071%, due 05/20/31	1.3%
Home Depot, Inc. (The), 4.750%, due 06/25/29	1.3%
Royal Bank of Canada, 1.150%, due 07/14/26	1.3%
Federal National Mortgage Association, 6.625%, due 11/15/30	1.3%
Freddie Mac Pool, 4.500%, due 01/1/41	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Limited-Term Bond Fund - Class C (ETCBX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETCBX

Eventide Limited-Term Bond Fund

Class I (ETIBX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class I	$48	0.47%

How has the Fund performed over the last ten years?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Limited-Term Bond Fund	Bloomberg U.S. 1-5 Year Government/Credit Index	Bloomberg U.S. Aggregate Bond Index
Jun-2016	$10,000	$10,000	$10,000
Jun-2017	$9,987	$10,011	$9,969
Jun-2018	$9,961	$9,991	$9,929
Jun-2019	$10,450	$10,525	$10,710
Jun-2020	$10,928	$11,096	$11,646
Jun-2021	$11,000	$11,140	$11,607
Jun-2022	$10,338	$10,561	$10,413
Jun-2023	$10,489	$10,581	$10,315
Jun-2024	$11,050	$11,074	$10,587
Jun-2025	$11,720	$11,785	$11,230
Jun-2026	$12,138	$12,139	$11,656

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	10 Years
Eventide Limited-Term Bond Fund - Class I	3.57%	1.99%	1.96%
Bloomberg U.S. 1-5 Year Government/Credit Index	3.00%	1.73%	1.96%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	1.54%

Fund Statistics

Table Summary
Net Assets	$218,186,572
Number of Portfolio Holdings	116
Advisory Fee (net of waivers)	$365,974
Portfolio Turnover	11%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.6%
Other Industries	14.6%
Construction Materials	2.0%
Asset Management	2.0%
Electrical Equipment	2.2%
Insurance	2.3%
Engineering & Construction	2.4%
Machinery	3.2%
Semiconductors	3.2%
Single-Family Housing	3.5%
Retail - Discretionary	5.5%
REIT	5.6%
Oil & Gas Producers	6.1%
Government Sponsored	6.2%
Electric Utilities	7.2%
Government Owned, No Guarantee	8.0%
Banking	9.6%
Agency Fixed Rate	13.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	2.0%
Corporate Bonds	65.1%
Municipal Bonds	4.1%
U.S. Government & Agencies	28.8%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.6%
Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31	1.4%
Duke Energy Florida, LLC, 2.500%, due 12/1/29	1.4%
Federal National Mortgage Association, 7.125%, due 01/15/30	1.4%
Federal Home Loan Mortgage Corporation, 4.125%, due 02/20/31	1.4%
Truist Financial Corporation, 5.071%, due 05/20/31	1.3%
Home Depot, Inc. (The), 4.750%, due 06/25/29	1.3%
Royal Bank of Canada, 1.150%, due 07/14/26	1.3%
Federal National Mortgage Association, 6.625%, due 11/15/30	1.3%
Freddie Mac Pool, 4.500%, due 01/1/41	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Limited-Term Bond Fund - Class I (ETIBX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETIBX

Eventide Limited-Term Bond Fund

Class N (ETNBX )

Annual Shareholder Report - June 30, 2026

Fund Overview

What were the Fund’s costs for the last year?

(based on a hypothetical $10,000 investment)

Table Summary
Class Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
Class N	$68	0.67%

How has the Fund performed since inception?

Total Return Based on $10,000 Investment

Table Summary
	Eventide Limited-Term Bond Fund	Bloomberg U.S. 1-5 Year Government/Credit Index	Bloomberg U.S. Aggregate Bond Index
Dec-2018	$10,000	$10,000	$10,000
Jun-2019	$10,464	$10,427	$10,708
Jun-2020	$10,921	$10,993	$11,644
Jun-2021	$10,974	$11,037	$11,605
Jun-2022	$10,287	$10,463	$10,411
Jun-2023	$10,419	$10,483	$10,313
Jun-2024	$10,959	$10,971	$10,585
Jun-2025	$11,595	$11,676	$11,228
Jun-2026	$11,986	$12,026	$11,653

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the Fund's investment universe.

How did the Fund perform during the reporting period?

Average Annual Total Returns

Table Summary
	1 Year	5 Years	Since Inception (12/14/2018)
Eventide Limited-Term Bond Fund - Class N	3.37%	1.78%	2.43%
Bloomberg U.S. 1-5 Year Government/Credit Index	3.00%	1.73%	2.48%
Bloomberg U.S. Aggregate Bond Index	3.79%	0.08%	2.05%

Fund Statistics

Table Summary
Net Assets	$218,186,572
Number of Portfolio Holdings	116
Advisory Fee (net of waivers)	$365,974
Portfolio Turnover	11%

What did the Fund invest in?

Industry Weighting (% of net assets)

Table Summary
Value	Value
Other Assets in Excess of Liabilities	2.6%
Other Industries	14.6%
Construction Materials	2.0%
Asset Management	2.0%
Electrical Equipment	2.2%
Insurance	2.3%
Engineering & Construction	2.4%
Machinery	3.2%
Semiconductors	3.2%
Single-Family Housing	3.5%
Retail - Discretionary	5.5%
REIT	5.6%
Oil & Gas Producers	6.1%
Government Sponsored	6.2%
Electric Utilities	7.2%
Government Owned, No Guarantee	8.0%
Banking	9.6%
Agency Fixed Rate	13.8%

Asset Weighting (% of total investments)

Table Summary
Value	Value
Asset Backed Securities	2.0%
Corporate Bonds	65.1%
Municipal Bonds	4.1%
U.S. Government & Agencies	28.8%

Top 10 Holdings* (% of net assets)

Table Summary
Holding Name	% of Net Assets
JPMorgan Chase & Company, 6.070%, due 10/22/27	1.6%
Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31	1.4%
Duke Energy Florida, LLC, 2.500%, due 12/1/29	1.4%
Federal National Mortgage Association, 7.125%, due 01/15/30	1.4%
Federal Home Loan Mortgage Corporation, 4.125%, due 02/20/31	1.4%
Truist Financial Corporation, 5.071%, due 05/20/31	1.3%
Home Depot, Inc. (The), 4.750%, due 06/25/29	1.3%
Royal Bank of Canada, 1.150%, due 07/14/26	1.3%
Federal National Mortgage Association, 6.625%, due 11/15/30	1.3%
Freddie Mac Pool, 4.500%, due 01/1/41	1.2%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund’s prospectus, and should not be considered investment advice.

Material Fund Changes

Eventide Limited-Term Bond Fund - Class N (ETNBX )

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund’s website (https://www.eventidefunds.com), including its:

Prospectus
Financial information
Holdings
Proxy voting information

TSR-AR 063026-ETNBX

Preparation of Federal & State income tax returns, assistance with calculation of required income, capital gain and excise distributions and preparation of Federal excise tax returns.

The Registrant’s schedule of investments in unaffiliated issuers is included in the Financial Statements under Item 7 of this form.

Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

Mutual Fund Series Trust (the “Trust”), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended (“1940 Act”) . The Trust currently consists of thirty-five series. These financial statements include the following series: Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund (each a “Fund” or collectively the “Funds”). Each Fund except Eventide Exponential Technologies Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund is a non-diversified series of the Trust. The Funds’ investment adviser is Eventide Asset Management, LLC (the “Adviser”).

Eventide Balanced Fund commenced operations on July 15, 2015. The Fund’s investment objective is current income while maintaining the potential for capital appreciation.

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund’s investment objective is total return consistent with income generation.

Eventide Dividend Growth Fund commenced operations on September 29, 2017. The Fund’s investment objectives are dividend growth and long term capital appreciation. The Fund’s secondary objective is dividend income.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund’s investment objective is long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund’s investment objective is long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund’s investment objective is long-term capital appreciation.

Eventide Large Cap Focus Fund commenced operations on June 30, 2022. The Fund’s investment objective is long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the “Conversion Date”). On the Conversion Date, each Class C share was reclassified as Class I shares equal in value to the Class C shares owned by that shareholder. The Fund’s investment objective is income.

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

Operating Segments- The Funds have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures. Adoption of the standard impacted financial statement disclosures only and did not affect each Fund’s financial position or the results of its operations. An operating segment is defined in Topic 280 as a component of a public entity that engages in business activities from which it may recognize revenues and incur expenses, has operating results that are regularly reviewed by the public entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and has discrete financial information available. Each Fund’s CODM is comprised of the portfolio manager(s) of the Fund and the Chief Financial Officer of the Trust. Each Fund operates as a single operating segment. Each Fund’s income, expenses, assets, changes in net assets resulting from operations and performance are regularly monitored and assessed as a whole by the CODM responsible for oversight functions of each Fund, using the information presented in the financial statements and financial highlights.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The Funds are investment companies and accordingly follow the investment company accounting and reporting guidance of the FASB Accounting Standards Codification Topic 946 “Financial Services – Investment Companies” including ASU 2013-08.

a) Securities Valuation – Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (“NOCP”). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the “Board”) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the “underlying funds”). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods

established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any -closed-end investment company purchased by the Funds will not-change. The independent pricing service does not distinguish between smaller sized bond positions known as “odd lots” and larger institutional sized bond positions known as “round lots”. The Funds may fair value a particular bond if the Adviser does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund’s holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

The Funds may hold investments, such as private investments, interests in commodity pools, other non-traded securities or temporarily illiquid securities, for which market quotations are not readily available or are determined to be unreliable. These securities were valued using the “fair value” procedures (the “Procedures”) pursuant to Rule 2a-5 approved by the Board. The Board has designated the Adviser as its valuation designee (the “Valuation Designee”) to execute these Procedures. The Board may also enlist third party consultants such as a valuation specialist at a public accounting firm, valuation consultant or financial officer of a security issuer, on an as-needed basis to assist the Valuation Designee in determining a security -specific fair value. The Board is responsible for reviewing and approving fair value methodologies utilized by the Valuation Designee, approval of which shall be based upon whether the Valuation Designee followed the valuation procedures established by the Board.

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Funds’ own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following tables summarize the inputs used as of June 30, 2026, for the Funds’ assets measured at fair value:

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

Transfers out of Level 3 during the period represent investments that are valued at transaction cost (level 3) and then moved to level 2 subsequently.

Transfers out of Level 3 during the period represent investments subject to an Initial Public Offering during the period.

The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investments were as follows:

The total change in unrealized appreciation or depreciation included in the Statements of Operations attributable to Level 3 investments still held at June 30, 2026, was $42,219 and $9,430,658 for the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, respectively.

b) Accounting for Options – When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the

sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

The Adviser may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the portfolio manager believes adverse market, political or other conditions are likely. The Adviser may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as “straddles,” “collars” or “spreads”) or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds (“ETFs”)) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

c) Short Sales – The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

d) Federal Income Tax – The Funds have qualified and intend to continue to qualify each year as regulated investment companies (“RIC”) under subchapter M of the Internal Revenue Code of 1986, as amended. By complying with the requirements applicable to RICs and annually distributing substantially all net investment company taxable income and net realized capital gains, no provision for federal income tax is required. The Funds recognize the tax benefits of uncertain tax positions only where the position is “more likely than not” to be sustained assuming examination by tax authorities. Management has reviewed the Funds’ tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken in the current tax year or on returns filed in previous tax years which are still open to examination by all major tax authorities (generally, federal returns are open to examination by the Internal Revenue Service for a period of three years from date of filing). The Funds recognize interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the Statements of Operations when incurred. During the fiscal year, the Funds did not incur any interest or penalties. The Funds typically intend to annually distribute sufficient net investment company taxable income and net realized capital gains if any, so that they will not be subject to the excise tax on undistributed income of RICs. If the required amount of net investment income or gains is not distributed annually, the Funds could incur a tax expense.

e) Distributions to Shareholders – Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains, interest and dividend income. Each Fund may make distributions (after any reductions for capital loss carry forwards) annually except for the Eventide Balanced Fund and Eventide Limited-Term Bond Fund, which are monthly, and the Eventide Dividend Growth Fund and Eventide Core Bond Fund, which are quarterly.

f) Multiple Class Allocations – Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

g) Security Transactions and Investment Income – Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the specific identified cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds’ understanding of the applicable country’s tax rules and rates. Distributions received from a Fund’s investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available. Distributions from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available.

h) Use of Estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) Indemnification – The Trust indemnifies its officers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds’ maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

j) Redemption Fees and Sales Charges (loads) – A $15 fee may be charged for redemptions made by wire. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds applies only to purchases of $250,000 or more and applies to shares sold within 18 months of purchase. The maximum deferred sales charge of 1.00% on Class C shares applies to shares sold within 12 months of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the year ended June 30, 2026, there were the following redemption fees paid to the Funds and CDSC fees paid to the distributor:

k) Cash and cash equivalents – Cash and cash equivalents are held with a financial institution. Cash and cash equivalents of the Funds may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The FDIC insures deposit accounts up to $250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Funds place deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

l) Redemptions in Kind – Each Fund reserves the right to honor requests for redemption or repurchase orders by making payment in whole or in part in readily marketable securities (“redemption in-kind”) if the amount is greater than the lesser of $250,000 or 1% of the Fund’s assets. The securities will be chosen by the Fund and valued under the Fund’s net asset value procedures. A shareholder will be exposed to market risk until these securities are converted to cash and may incur transaction expenses in converting these securities to cash

For the year ended June 30, 2026, aggregate purchases and proceeds from sales of investment securities (excluding in-kind transactions and short-term investments) for the Funds were as follows:

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of an investment advisory agreement between the Adviser and the Trust (the “Advisory Agreement”). Boyd Watterson Asset Management, LLC serves as sub-adviser to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Balanced Fund’s portfolio. Under the terms of the Advisory Agreement, the Adviser directs the investment operations of the Funds in accordance with the Funds’ investment policies and restrictions. The Adviser provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. The fees paid by the Funds to the Adviser are described in greater detail below. The Adviser pays expenses incurred by it in connection with acting as investment adviser to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Advisory Agreement).

The Adviser pays for all employees, office space and facilities required by it to provide services under the Advisory Agreement, with the exception of specific items of expense (as detailed in the Advisory Agreement). For the year ended June 30, 2026 advisory fees before the waivers and reimbursements described below.

Each Fund is authorized to pay the Adviser an annual fee based on its average daily net assets. The advisory fee is paid monthly. The Adviser has contractually agreed to waive fees and/or reimburse expenses, but only to the extent necessary to maintain each Fund’s total annual operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at a certain level through October 31, 2026. This agreement may be terminated by the Board only on 60 days’ written notice to the Adviser and upon the termination of the Advisory Agreement between the Trust and the Adviser. Fee waivers and expense reimbursements are subject to possible recoupment by the Adviser from the Funds in future years on a rolling three-year basis (within the three years after the fees

have been waived or reimbursed) if, after the recoupment is taken into account, such recoupment can be achieved within the lesser of the expense limitation in place at the time of waiver/reimbursement and the expense limitation in place at the time of recapture. Each waiver or reimbursement by the Adviser is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board.

The following table lists the contractual advisory fee and the expense limitation for each Fund.

As of June 30, 2026, the Adviser has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund do not have any expenses previously waived by the Adviser that are subject to recapture and did not waive any further expenses during the year ended June 30, 2026. Eventide Dividend Growth Fund recaptured $104,555 expense during the year ended June 30, 2026.

Pursuant to the management services agreement between the Trust and MFund Services, LLC (“MFund”), MFund provides the Funds with management and legal administrative services (the “Management Services Agreement”). For these services, the Funds pay MFund an annual asset-based fee in accordance with the following schedule applied at the Fund family level (i.e., all the Funds in the Trust advised by the Adviser): 0.10% of net assets up to $50 million; 0.07% of net assets from $50 million to $100 million; 0.05% of net assets from $100 million to $250 million; 0.04% of net assets from $250 million to $500 million; 0.03% of net assets from $500 million to $1 billion; 0.02% of net assets from $1 billion to $5 billion; and 0.01% of assets from $5 billion and above. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Management Services Agreement. The amounts due to MFund for the Management Services Agreement are listed in the Statements of Assets and Liabilities under “Payable to related parties” and the amounts accrued for the year are shown in the Statements of Operations under “Legal administration fees/management service fees.”

Pursuant to the compliance services agreement between the Trust and MFund (the “Compliance Services Agreement”), MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund $1,200 per month for the first fund in the fund family and $400 each additional fund; $400 for each adviser and sub-adviser; and .0025% of the assets of each Fund. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Compliance Services Agreement.

Amounts due to MFund for chief compliance officer services as of June 30, 2026 are shown in the Statement of Assets and Liabilities under “Compliance officer fees payable,” and the amounts accrued for the period are shown in the Statements of Operations under “Compliance officer fees.”

A trustee of the Trust is also the controlling member of MFund and the investment advisers to other series of the Trust and is not paid any fees directly by the Trust for serving in such capacities. Trustees who are not “interested persons” as that term is defined in the 1940 Act are paid a quarterly retainer and receive compensation for each special Board meeting and Risk and Compliance Committee meeting attended. The fees paid to the Independent Trustees for attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust, the Chairman of the Trust’s Audit Committee and the Chairman of the Risk and Compliance Committee receive an additional quarterly retainer. The “interested persons” of the Trust receive no compensation from the Funds. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

Ultimus Fund Solutions, LLC (“UFS”), an affiliate of the distributor, provides administrative, fund accounting, and transfer agency services to the Funds pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (“Blu Giant”), an affiliate of UFS and the distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

The Trust’s officers are not paid any fees directly by the Trust for serving in such capacity except for the chief compliance officer.

The Trust has adopted a Master Distribution Plan Pursuant to Rule 12b-1 (the “Plan”) under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC (the “Distributor”) and the Adviser for distribution related expenses.

For the year ended June 30, 2026, the Distributor received the following in underwriter commissions from the sale of Class A and Class C shares.

The following table represents aggregate cost for federal tax purposes, including options written, for the Funds as of June 30, 2026 and differs from market value by net unrealized appreciation/depreciation which consisted of:

The tax character of fund distributions for the years ended June 30, 2026, and June 30, 2025, was as follows:

As of June 30, 2026, the components of accumulated earnings/(deficit) on a tax basis were as follows:

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, mark-to-market on passive foreign investment companies, adjustments for C-Corporation return of capital and perpetual bonds. In addition, the amounts listed under other book/tax differences are primarily attributable to the tax deferral of losses on straddles.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such late year losses as follows:

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

At June 30, 2026, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains and utilized prior year capital loss carry forwards, as follows:

During the fiscal year ended June 30, 2026, certain of the Funds utilized tax equalization which is the use of earnings and profits distributions to shareholders on redemption of shares as part of the dividends paid deduction for income tax purposes. Permanent book and tax differences, primarily attributable to the book/tax basis treatment of net operating losses, distributions in excess, tax adjustments for realized gain (loss) on in-kind redemptions and use of tax equalization credits, resulted in reclassifications for the Funds for the fiscal year ended June 30, 2026, as follows:

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at June 30, 2026 are noted in the Funds’ Schedule of Investments. Transactions during the period with companies which are affiliates are as follows:

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund’s investment objectives and investment strategies. A Fund will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of the Fund’s net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer’s expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of June 30, 2026, the Eventide Core Bond Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund and Eventide Limited-Term Bond Fund were invested in the following restricted securities:

The Eventide Exponential Technologies Fund invests primarily in equity and equity -related securities of companies that the Adviser believes are participating in and benefitting from technologies, innovations, technology themes, or technology trends. The types of companies represented in the Fund’s portfolio include, but are not limited to, companies falling within the information technology, internet media and services, healthcare technology, healthcare devices, or financial technology (i.e., Fintech) industries. Because of its focus on technology companies, the Eventide Exponential Technologies Fund’s investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Exponential Technologies Fund’s net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund’s investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund’s net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

Overall market risks may also affect the value of the Funds. The market values of securities or other investments owned by the Funds will go up or down, sometimes rapidly or unpredictably. Factors such as economic growth and market conditions, interest rate levels, exchange rates and political events affect the securities markets. Changes in market conditions and interest rates generally do not have the same impact on all types of securities and instruments. Unexpected local, regional or global events and their aftermath, such as war; acts of terrorism; financial, political or social disruptions; natural, environmental or man-made disasters; climate-change and climate-related events; the spread of infectious illnesses or other public health issues; recessions and depressions; tariffs and trade wars; or other tragedies, catastrophes and events could have a significant impact on the Funds and their investments and could result in increased premiums or discounts to a Fund’s net asset value, and may impair market liquidity, thereby increasing liquidity risk. Such events can cause investor fear and panic, which can adversely affect the economies of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen. The Funds could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. In times of severe market disruptions you could lose your entire investment.

The Funds have a $150,000,000 uncommitted line of credit provided by U.S. Bank National Association (the “Bank”) under an agreement (the “Uncommitted Line”), that is set to expire on January 21, 2027. Borrowings under the Uncommitted Line bear an interest at Prime Rate minus 0% per month. Any advance under the Uncommitted Line is contemplated primarily for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. Interest on borrowings is payable on an annualized basis. The Uncommitted Line is not a “committed” line of credit, which is to say that the Bank is not obligated to lend money to the Funds. Accordingly, it is possible that Funds may wish to borrow money for a temporary or emergency purpose but may not be able to do so. During the year ended June 30, 2026, none of the Funds accessed the line of credit.

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of June 30, 2026, Charles Schwab & Co, Inc. for the Exclusive Benefit of Customers held 29.92%, 35.49%, and 25.84% of the Eventide Core Bond Fund, Eventide Exponential Technologies Fund, and Eventide Limited-Term Bond Fund, respectively. As of June 30, 2026, National Financial Services LLC held 36.27% of the Eventide Core Bond Fund. As of June 30, 2026, American Enterprise Investment Services held 29.73% of the Eventide Limited-Term Bond Fund.

The Funds adopted FASB ASU 2023-09, “Income Taxes (Topic 740) Improvements to Income Tax Disclosures” (“ASU 2023-09”), which establishes new income tax disclosure requirements and modifies or eliminates certain existing disclosure provisions. The amendments in this ASU are intended to address investor requests for more transparency about income tax information and to improve the effectiveness of income tax disclosures. The Fund’s adoption of ASU 2023-09 did not have a material impact on the Funds’ financial statements.

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

To the Shareholders of Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund and
Board of Trustees of Mutual Fund Series Trust

We have audited the accompanying statements of assets and liabilities, including the schedules of investments, of Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund (the “Funds”), each a series of Mutual Fund Series Trust, as of June 30, 2026, the related statements of operations for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the four years in the period then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of each of the Funds as of June 30, 2026, the results of their operations for the year then ended, the changes in net assets for each of the two years in the period then ended, and the financial highlights for each of the four years in the period then ended, in conformity with accounting principles generally accepted in the United States of America.

The Funds’ financial highlights for the year ended June 30, 2022 were audited by other auditors whose report dated August 29, 2022, expressed an unqualified opinion on those financial highlights.

These financial statements are the responsibility of the Funds’ management. Our responsibility is to express an opinion on the Funds’ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of June 30, 2026, by correspondence with the custodian, issuers and brokers; when replies were not received from issuers and brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

There were no changes in or disagreements with accountants during the period covered by this report.

Consideration and Renewal of Management Agreement between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to Eventide Gilead Fund, Eventide Healthcare and Life Sciences Fund, Eventide Balanced, Eventide Dividend Growth Fund, Eventide Limited-Term Bond Fund, Eventide Exponential Technologies Fund, Eventide Core Bond Fund and Eventide Large Cap Focus Fund.

In connection with a meeting held on May 13, 14 and 27, 2026 the Board of Trustees (the “Board”) of Mutual Fund Series Trust (the “Trust”), including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the renewal of the advisory agreement (the “Advisory Agreement”) between the Trust and Eventide Asset Management, LLC (“Eventide”) with respect to Eventide Gilead Fund (“Eventide Gilead”), Eventide Healthcare and Life Sciences Fund (“Eventide HLS”), Eventide Balanced Fund (“Eventide Balanced”), Eventide Dividend Growth Fund (“Eventide DG”), Eventide Limited-Term Bond Fund (“Eventide LTB”), Eventide Exponential Technologies Fund (“Eventide ET”), Eventide Core Bond Fund (“Eventide CB”) and Eventide Large Cap Focus Fund (“Eventide LCF”) (collectively, the “Eventide Funds”)

The Board examined Eventide’s responses to a series of questions regarding, among other things, its advisory services provided to the Eventide Funds, comparative fee and expense information, and profitability from managing the Eventide Funds. The Board was assisted by legal counsel throughout the review process and relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Advisory Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to the renewal of the Advisory Agreement.

Nature, Extent and Quality of Services. The Board reviewed the key personnel involved in servicing the Eventide Funds, noting that there had been some changes but that key investment personnel remained consistent since the most recent renewal of the Eventide Agreement. The Board added that a new portfolio manager had been added for Eventide ET. The Board observed that Eventide was responsible for providing portfolio management services to the Eventide Funds, including research and analysis, making investment decisions, and security selection consistent with the value principles articulated in each Eventide Fund’s prospectus. The Board discussed that Eventide utilized internal research analysts and portfolio managers to provide fundamental security and sector research, as well as external research partners to provide sector and macro-economic data. The Board noted that Eventide had strong internal research capabilities and utilized this research in serving the Eventide Funds. The Board recognized that Eventide provided continuous oversight and compliance services to the Eventide Funds that were sub-advised by Boyd Watterson. After further discussion, the Board concluded Eventide could continue to provide high quality service to each Eventide Fund and its shareholders.

Performance. The Board reviewed the performance of each Eventide Fund relative to its peer group and Morningstar category.

Eventide Gilead: The Board observed that Eventide Gilead greatly outperformed the peer group average, Morningstar category, and benchmark index for the 1-year period but underperformed each benchmark for the 3-year and 5-year periods. The Board noted Eventide Gilead outperformed all benchmarks for the 10-year period. The Board noted that Eventide explained that the underperformance in the 3-year period was largely due to general stock selection in the portfolio and allocations to the Financials, Industrial and Consumer Discretionary Sectors while underperformance in the 5-year period was attributed to allocations to the Financials, Industrials, and Communication Services sectors.

Eventide HLS: The Board discussed that Eventide HLS significantly outperformed all benchmarks for the 1-year period and outperformed all benchmarks for the 10-year period. The Board noted Eventide HLS outperformed the peer group and Morningstar category for the 3-year period but underperformed the 5-year period and underperformed the S&P Biotechnology Select Industry TR Index for the 3- year period but outperformed for the 5-year period. The Board noted that Eventide explained that the Morningstar category and peer group funds included less biotechnology securities with a focus on insurance companies which led to the differences in performance.

Eventide Balanced: The Board noted that Eventide Balanced underperformed the peer group average for all time periods but outperformed the Bloomberg Mid Cap/Intermediate US Aggregate index for the 3-, 5-, and 10-year periods. The Board reviewed that Eventide Balanced underperformed the US Fund Moderate Allocation Morningstar category for all time periods but outperformed the US Fund Conservative Allocation Morningstar category for all time periods. The Board acknowledged that Eventide noted that the peer group funds and US Fund Moderate Allocation Morningstar category had higher equity exposure than Eventide Balanced which led to the consistent underperformance.

Eventide DG: The Board noted that Eventide DG underperformed all benchmarks for the 1-year period but outperformed all benchmarks for the 3-year and 5-year periods and outperformed all benchmarks other than the benchmark index for the 10-year period. The Board noted that Eventide explained that the underperformance was due to underperformance in the Financials, Materials, Consumer Discretionary, Utilities, and Information Technology Sectors

Eventide LTB: The Board observed that Eventide LTB outperformed all benchmarks for the 1-year period but underperformed the peer group and US Fund Short Term Bond Morningstar category for all other time periods. The Board noted Eventide LTB slightly outperformed the Bloomberg US Govt/Credit 1-5 Yr TR Index for the 3-year period but slightly underperformed for the 5-year and 10-year periods. The Board observed that Eventide reported that corporate bonds contributed to Eventide LTB’s performance and that the longer duration in Eventide LTB’s bonds compared to funds in the peer group led to the underperformance.

Eventide ET: The Board discussed that Eventide ET underperformed all benchmarks for all time periods. The Board noted that Eventide attributed the underperformance to security selection in the portfolio and the lack of large cap information technology securities. The Board noted that Eventide explained that very few of the top performing information technology companies in recent years were eligible for inclusion in the portfolio because of Eventide’s ethical screen. The Board acknowledged Eventide recently added a new portfolio manager to Eventide ET.

Eventide CB: The Board observed that Eventide CB outperformed all benchmarks for the 1-year period and outperformed the peer group for the 3-year period but underperformed the peer group for the 5-year and since inception periods. The Board noted Eventide CB underperformed the US Fund Intermediate Core Bond category, and Bloomberg US Aggregate Bond TR Index for the 3-year, 5-year, and since inception periods. The Board discussed that Eventide attributed the underperformance primarily to the timing of Eventide CB’s launch coinciding with the start of rising interest rates and its underweight allocation to treasury bonds.

Eventide LCF: The Board observed that Eventide LCF trailed all benchmarks for all time periods. The Board reviewed that Eventide attributed the consistent underperformance compared to Eventide LCF’s allocations in the Financials, Communications Services, and Materials sectors.

After further discussion, the Board concluded that the performance of each Eventide Fund was acceptable.

Fees and Expenses: The Board discussed the advisory fees paid by each of the Eventide Funds in comparison to the fees charged to the peer group funds, and the funds in each of the Eventide Funds’ Morningstar category along with the indirect benefits of Rule 12b-1 fees received by Eventide with respect to the distribution of the Eventide Funds. The Board reviewed the allocation of fees between Eventide and Boyd Watterson, based on the sub-advisory fees paid by the advisor for each of Eventide Balanced, Eventide CB and Eventide LTB, in comparison to the level of service provided. The Board noted that the sub-advisory agreement between Eventide and Boyd Watterson was the product of an arm’s length negotiation.

Eventide Gilead: The Board observed that the advisory fee of 0.98% was above the median and average for the peer group and Morningstar category but within the range for both. The Board noted that the net expense ratio of 1.43% was above the peer group and Morningstar category median and average but within the range for each.

Eventide HLS: The Board reviewed that the advisory fee for Eventide HLS of 1.10% was above the median and average for the peer group and Morningstar category but within the range. The Board noted that the net expense ratio of 1.56% was higher than the median and average for the peer group and Morningstar category but well below the high for each.

Eventide Balanced: The Board discussed that the advisory fee for Eventide Balanced was in line with the average for the peer group but above the median and above the median and average for the Morningstar category but well below the high. The Board noted that the net expense ratio was above the peer group median but in line with the average and was above the average for the Morningstar category but within the range of each.

Eventide DG: The Board acknowledged that the advisory fee of 0.73% (before recoupment) was below the median and in line with average for the peer group, above the median and average for the Morningstar category but within the range. The Board discussed

that the net expense ratio was above the median and average for the peer group and Morningstar category but well below the highs for each.

Eventide LTB: The Board noted that the advisory fee of 0.31% (before waiver) was below the median and average for both the peer group and Morningstar category. The Board observed that the net expense ratio was below the median and average for the peer group and Morningstar category.

Eventide ET: The Board reviewed that the advisory fee was above the median and average for the peer group and Morningstar category but within the range for each. The Board discussed that the net expense ratio was above the peer group and Morningstar category median and average but well below the highs for each.

Eventide CB: The Board observed the advisory fee was below the median and average for the peer group and in line with the Morningstar category. The Board discussed that the net expense ratio was below the median and average for the peer group and in line with median and average for the Morningstar category.

Eventide LCF: The Board discussed that Eventide LCF’s advisory fee of 0.73% (before waivers) was above the peer group and Morningstar category median and average but within the range for each. The Board discussed that the net expense ratio was above the peer group and Morningstar category median and average but well below the highs for each.

The Board determined that based on the advisory services provided to each of the Eventide Funds by Eventide that the advisory fee paid by each of the Eventide Funds to Eventide was not unreasonable.

Profitability. The Board discussed the financial information provided by Eventide and reviewed Eventide’s profitability from its services to each of the Eventide Funds. The Board recognized that Eventide earned a reasonable profit from advising Eventide Gilead, Eventide HLS, Eventide Balanced, Eventide DG, Eventide ET, and Eventide LCF but did not earn a profit from advising Eventide LTB or Eventide CB. The Board acknowledges the soft dollar benefits Eventide received, and, after further discussion, agreed excess profitability on a fund-by-fund basis was not a concern at this time.

Economies of Scale. The Board discussed potential breakpoints for the Eventide Funds, but acknowledged that Eventide Fund’s shareholders benefited from each Eventide Fund’s expense cap. The Board recognized that Eventide paid a sub-advisory fee for each of Eventide Balanced, Eventide CB and Eventide LTB. After further discussion, the Board concluded breakpoints were not appropriate at this time, but that it would continue to discuss breakpoints in the future.

Conclusion. Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Advisory Agreement, and as assisted by the advice of counsel, the Board concluded that renewal of the advisory agreement was in the best interests of each Eventide Fund and its respective shareholders

Information regarding how the Funds voted proxies relating to portfolio securities for the most recent 12-month period ended June 30 as well as a description of the policies and procedures that the Funds use to determine how to vote proxies is available without charge, upon request, by calling 1-877-771-3836 or by referring to the Securities and Exchange Commission’s (“SEC”) website at http://www.sec.gov.

Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.

Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.

Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.

Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.

Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.

(a) The registrant’s Principal Executive Officer and Principal Financial Officer have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act) are effective in design and operation and are sufficient to form the basis of the certifications required by Rule 30a-(2) under the Act, based on their evaluation of these disclosure controls and procedures as of a date within 90 days of this report on Form N-CSR.

(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.

(a)(3) A separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)): Attached hereto.

(b) Certifications required by Rule 30a-2(b) under the Act (17 CFR 270.30a-2(b)): Attached hereto.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

225 Pictoria Drive, Suite 450, Cincinnati, OH	45246
(Address of principal executive offices)	(Zip code)

Date of fiscal year end:	6/30

Date of reporting period:	6/30/2026

(a)	The registrant has, as of the end of the period covered by this report, adopted a code of ethics that applies to the registrant’s principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals are employed by the registrant or a third party.

(b)	N/A

(c)	During the period covered by this report, there were no amendments to any provision of the code of ethics.

(d)	During the period covered by this report, there were no waivers or implicit waivers of a provision of the code of ethics.

(e)	N/A

(f)	See Item 19(a)(1)

Trust Series	2026	2025
Eventide Gilead Fund	62,062	66,582
Eventide Dividend Growth Fund	28,395	25,966
Eventide Healthcare & Life Sciences Fund	33,879	31,952
Eventide Limited Term Bond Fund	7,832	7,266
Eventide Balanced Fund	11,678	12,170
Eventide Core Bond Fund	7,340	7,131
Eventide Exponential Technologies Fund	5,798	6,259
Eventide Large Cap Focus Fund	7,516	7,174

(b)	Audit-Related Fees. There were no fees billed in each of the last two fiscal years for assurances and related services by the principal accountant that are reasonably related to the performance of the audit of the registrant’s financial statements and are not reported under paragraph (a) of this Item.

(c)	Tax Fees. The aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance are as follows:

(d)	All Other Fees. The aggregate fees billed in each of the last two fiscal years for products and services provided by the registrant’s principal accountant, other than the services reported in paragraphs (a) through (c) of this item were $0 and $0 for the fiscal years ended June 30, 2026 and 2025 respectively.

(e)(1)	The audit committee does not have pre-approval policies and procedures. Instead, the audit committee or audit committee chairman approves on a case-by-case basis each audit or non-audit service before the principal accountant is engaged by the registrant.

(e)(2)	There were no services described in each of paragraphs (b) through (d) of this Item that were approved by the audit committee pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

(f)	Not applicable.

(g)	All non-audit fees billed by the registrant’s principal accountant for services rendered to the registrant for the fiscal years ended June 30, 2026 and 2025 respectively are disclosed in (b)-(d) above. There were no audit or non-audit services performed by the registrant’s principal accountant for the registrant’s adviser.

(h)	Not applicable.

(i)	Not applicable.

(j)	Not applicable.

Shares			Fair Value
		COMMON STOCKS — 54.4%
		BANKING - 1.1%
	39,409	Fifth Third Bancorp	$	2,221,485
	124,337	Huntington Bancshares Inc		2,204,495
				4,425,980
		BIOTECH & PHARMA - 2.1%
	150,555	Royalty Pharma plc, Class A		8,441,619

		CHEMICALS - 2.0%
	105,338	Element Solutions, Inc.		5,029,889
	8,106	Sherwin-Williams Company (The)		2,791,058
				7,820,947
		COMMERCIAL SUPPORT SERVICES - 1.0%
	98,054	Rollins, Inc.		4,092,774

		CONSTRUCTION MATERIALS - 0.6%
	4,284	Martin Marietta Materials, Inc.		2,470,583

		ELECTRIC UTILITIES - 4.1%
	27,736	Black Hills Corporation		2,063,558
	5,817	Constellation Energy Corporation		1,444,768
	74,066	Entergy Corporation		8,507,221
	15,311	Vistra Corporation		2,428,784
	18,108	WEC Energy Group, Inc.		2,114,471
				16,558,802
		ELECTRICAL EQUIPMENT - 8.3%
	6,689	GE Vernova, Inc.		7,858,639
	67,316	nVent Electric PLC		11,417,467
	3,698	Rockwell Automation, Inc.		1,830,806
	24,016	Trane Technologies PLC		11,795,698
				32,902,610
		ENGINEERING & CONSTRUCTION - 0.9%
	619	Comfort Systems USA, Inc.		1,226,827
	3,039	Quanta Services, Inc.		2,188,202
				3,415,029

Shares			Fair Value
		COMMON STOCKS — 54.4% (Continued)
		GAS & WATER UTILITIES - 1.0%
	80,131	NiSource, Inc.	$	3,810,229

		HOME CONSTRUCTION - 0.9%
	21,353	DR Horton, Inc.		3,477,977

		INDUSTRIAL REIT - 3.0%
	29,425	EastGroup Properties, Inc.		5,959,445
	43,631	Prologis, Inc.		5,910,692
				11,870,137
		INDUSTRIAL SUPPORT SERVICES - 2.0%
	18,201	Applied Industrial Technologies, Inc.		6,154,668
	1,656	United Rentals, Inc.		1,876,066
				8,030,734
		INSTITUTIONAL FINANCIAL SERVICES - 2.5%
	26,784	Houlihan Lokey, Inc.		3,592,538
	82,025	Nasdaq, Inc.		6,465,211
				10,057,749
		INSURANCE - 0.9%
	10,087	Arthur J. Gallagher & Company		2,315,673
	5,255	Willis Towers Watson PLC		1,373,499
				3,689,172
		MACHINERY - 1.1%
	14,053	IDEX Corporation		3,189,329
	17,958	Pentair PLC		1,376,660
				4,565,989
		MEDICAL EQUIPMENT & DEVICES - 1.4%
	25,747	STERIS plc		5,421,546

		OIL & GAS PRODUCERS - 5.2%
	7,275	Diamondback Energy, Inc.		1,278,800
	32,723	DT Midstream, Inc.		4,801,773
	30,642	Targa Resources Corporation		8,216,346
	84,445	Williams Companies, Inc. (The)		6,277,641
				20,574,560

Principal				Coupon Rate
Amount ($)				(%)	Maturity	Fair Value
		ASSET BACKED SECURITIES — 1.1%
		AUTO LOAN — 1.1%
	2,230,000	CarMax Auto Owner Trust 2024-2 D		6.4200	10/15/30	$	2,279,731
	1,375,000	CarMax Auto Owner Trust 2026-2 A4		4.3100	06/15/32		1,366,218
	540,000	CarMax Auto Owner Trust 2026-2 C		4.7500	06/15/32		536,039
							4,181,988
		TOTAL ASSET BACKED SECURITIES (Cost$4,196,784)					4,181,988

Principal				Coupon Rate
Amount ($)				(%)	Maturity	Fair Value
		COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%
		CMBS — 0.5%
	1,000,000	Freddie Mac Multifamily Structured Pass Through Series KG01 A10		2.9390	04/25/29		957,398
	1,000,000	Freddie Mac Multifamily Structured Pass Through Series KG02 A2		2.4120	08/25/29		945,826
							1,903,224
		TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,019,589)					1,903,224

Principal				Coupon Rate
Amount ($)			Spread	(%)	Maturity	Fair Value
		CORPORATE BONDS — 20.7%
		ASSET MANAGEMENT — 0.4%
	1,700,000	HA Sustainable Infrastructure Capital, Inc.		6.1500	01/15/31		1,744,658

		BANKING — 3.2%
	1,500,000	Citizens Financial Group, Inc.^(b)	SOFRRATE + 1.259%	5.2530	03/05/31		1,517,239
	2,300,000	First Horizon Corporation^(b)	SOFRRATE + 1.766%	5.5140	03/07/31		2,330,953
	2,200,000	Huntington Bancshares, Inc.^(b)	SOFRINDX + 1.870%	5.7090	02/02/35		2,254,649
	3,200,000	JPMorgan Chase & Company^(b)	SOFRRATE + 1.330%	6.0700	10/22/27		3,215,972
	2,250,000	M&T Bank Corporation^(b)	SOFRRATE + 0.930%	4.8330	01/16/29		2,256,494
	1,250,000	Truist Financial Corporation Series I^(b)	SOFRRATE + 1.309%	5.0710	05/20/31		1,262,598
							12,837,905
		BIOTECH & PHARMA — 0.3%
	1,000,000	Eli Lilly & Company		5.1000	02/12/35		1,017,516

CMBS	- Commercial Mortgage Backed Security

LTD	- Limited Company

LLC	- Limited Liability Company

L.P.	- Limited Partnership

MSCI	- Morgan Stanley Capital International

N.V.	- Naamioze Vennootschap

PLC	- Public Limited Company

REIT	- Real Estate Investment Trust

SOFRINDX	United States SOFR Index

SOFRRATE	United States SOFR Secured Overnight Financing Rate

^(a)	Non-income producing security.

^(b)	Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

^(c)	Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2026 the total market value of 144A securities is $19,925,745 or 5.0% of net assets.

^(d)	Percentage rounds to less than 0.1%.

^(e)	Rate disclosed is the seven day effective yield as of June 30, 2026.

^(a)	Illiquid security. The total fair value of these securities as of June 30, 2026, was $2,217,521, representing 1.0% of net assets.

^(b)	Restricted security. See Note 6 for additional details.

^(c)	Private investment.

^(d)	Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

^(e)	Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2026 the total market value of 144A securities is $9,279,116 or 4.3% of net assets.

Shares			Fair Value
		COMMON STOCKS — 98.3%
		BANKING - 2.0%
	254,739	Fifth Third Bancorp	$	14,359,637
	803,722	Huntington Bancshares Inc		14,249,991
				28,609,628
		BIOTECH & PHARMA - 3.0%
	774,108	Royalty Pharma plc, Class A		43,404,236

		CHEMICALS - 4.0%
	876,042	Element Solutions, Inc.		41,831,006
	44,122	Sherwin-Williams Company (The)		15,192,087
				57,023,093
		COMMERCIAL SUPPORT SERVICES - 3.3%
	567,386	Rollins, Inc.		23,682,692
	231,814	UL Solutions, Inc., Class A		23,612,574
				47,295,266
		CONSTRUCTION MATERIALS - 1.1%
	27,579	Martin Marietta Materials, Inc.		15,904,809

		CONTAINERS & PACKAGING - 0.6%
	206,293	International Paper Company		7,859,763

		ELECTRIC UTILITIES - 8.0%
	168,995	Black Hills Corporation		12,573,228
	37,206	Constellation Energy Corporation		9,240,854
	440,807	Entergy Corporation		50,631,092
	36,052	Talen Energy Corporation^(a)		13,853,341
	105,546	Vistra Corporation		16,742,762
	98,223	WEC Energy Group, Inc.		11,469,500
				114,510,777
		ELECTRICAL EQUIPMENT - 12.8%
	38,219	GE Vernova, Inc.		44,901,974
	395,073	nVent Electric PLC		67,008,332
	142,596	Trane Technologies plc		70,037,451
				181,947,757

Shares			Fair Value
		COMMON STOCKS — 98.3% (Continued)
		ENGINEERING & CONSTRUCTION - 1.2%
	3,807	Comfort Systems USA, Inc.	$	7,545,284
	13,550	Quanta Services, Inc.		9,756,542
				17,301,826
		GAS & WATER UTILITIES - 1.5%
	448,657	NiSource, Inc.		21,333,640

		HEALTH CARE FACILITIES & SERVICES - 0.4%
	61,913	Encompass Health Corporation		6,258,166

		HOME CONSTRUCTION - 1.8%
	154,616	DR Horton, Inc.		25,183,854

		INDUSTRIAL REIT - 5.0%
	177,885	EastGroup Properties, Inc.		36,027,049
	259,481	Prologis, Inc.		35,151,891
				71,178,940
		INDUSTRIAL SUPPORT SERVICES - 3.6%
	105,853	Applied Industrial Technologies, Inc.		35,794,192
	13,959	United Rentals, Inc.		15,814,012
				51,608,204
		INSTITUTIONAL FINANCIAL SERVICES - 4.3%
	172,973	Houlihan Lokey, Inc.		23,200,868
	487,168	Nasdaq, Inc.		38,398,582
				61,599,450
		INSURANCE - 1.8%
	59,739	Arthur J. Gallagher & Company		13,714,282
	47,789	Willis Towers Watson PLC		12,490,611
				26,204,893
		MACHINERY - 1.9%
	74,132	IDEX Corporation		16,824,258
	134,870	Pentair PLC		10,339,134
				27,163,392
		MEDICAL EQUIPMENT & DEVICES – 3.9%
	19,974	Mettler-Toledo International, Inc.^(a)		25,516,985

Shares			Fair Value
		COMMON STOCKS — 90.3%
		AEROSPACE & DEFENSE - 1.8%
	3,307	Axon Enterprise, Inc.^(a)	$	1,853,937

		BIOTECH & PHARMA - 4.3%
	173,298	Beta Bionics, Inc.^(a)		2,715,580
	31,107	Vaxcyte, Inc.^(a)		1,808,250
				4,523,830
		ELECTRICAL EQUIPMENT - 5.6%
	4,964	Advanced Energy Industries, Inc.		1,850,927
	10,919	Generac Holdings, Inc.^(a)		3,197,192
	2,616	Vertiv Holdings Company, Class A		875,889
				5,924,008
		INDUSTRIAL INTERMEDIATE PROD - 2.9%
	32,316	Xometry, Inc., Class A^(a)		3,119,140

		MEDICAL EQUIPMENT & DEVICES - 10.6%
	18,415	Dexcom, Inc.^(a)		1,240,250
	7,337	Glaukos Corporation^(a)		1,025,419
	36,039	Guardant Health, Inc.^(a)		5,406,931
	13,017	iRhythm Technologies, Inc.^(a)		1,548,372
	76,979	Kestra Medical Technologies, Inc.^(a)		1,958,346
				11,179,318
		OIL & GAS SERVICES & EQUIPMENT - 3.9%
	79,163	Liberty Energy, Inc., Class A		2,073,279
	25,219	Solaris Oilfield Infrastructure, Inc., Class A		2,029,121
				4,102,400
		SEMICONDUCTORS - 38.8%
	8,827	Advanced Micro Devices, Inc.^(a)		5,127,692
	2,622	Applied Materials, Inc.		1,895,706
	1,264	ARM Holdings PLC - ADR^(a)		448,176
	1,023	ASML Holding N.V. - ADR		2,035,197
	3,895	Broadcom, Inc.		1,471,336
	2,163	Coherent Corp.^(a)		853,239
	5,634	Infineon Technologies A.G. - ADR		529,371
	4,580	KLA Corporation		1,381,832

Shares			Fair Value
		COMMON STOCKS — 90.3% (Continued)
		SEMICONDUCTORS - 38.8% (Continued)
	9,782	Lam Research Corporation	$	4,238,834
	17,034	Lattice Semiconductor Corporation^(a)		2,605,521
	5,927	Micron Technology, Inc.		6,841,477
	585	Monolithic Power Systems, Inc.		808,681
	27,793	NVIDIA Corporation		5,561,101
	1,434	NXP Semiconductors N.V.		402,997
	2,860	Qualcomm, Inc.		528,499
	617	Sandisk Corporation^(a)		1,402,891
	1,493	SiTime Corporation^(a)		1,113,121
	6,729	Taiwan Semiconductor Manufacturing Company Ltd. - ADR		3,213,569
	1,294	Teradyne, Inc.		626,089
				41,085,329
		SOFTWARE - 10.2%
	2,796	Cadence Design Systems, Inc.^(a)		1,049,395
	962	Crowdstrike Holdings, Inc., Class A^(a)		734,141
	2,324	Datadog, Inc., Class A^(a)		605,077
	3,206	Fortinet, Inc.^(a)		492,506
	41,900	HeartFlow, Inc.^(a)		1,229,346
	4,100	MongoDB, Inc.^(a)		1,377,190
	7,013	Palo Alto Networks, Inc.^(a)		2,391,573
	12,567	ServiceTitan, Inc., Class A^(a)		888,612
	8,199	Shopify, Inc., Class A^(a)		936,162
	4,265	Snowflake, Inc. ^(a)		1,085,442
				10,789,444
		TECHNOLOGY HARDWARE - 9.6%
	19,673	Arista Networks, Inc.^(a)		3,342,049
	14,168	Cisco Systems, Inc.		1,664,173
	1,947	Dell Technologies, Inc., Class C		840,053
	1,548	Fabrinet^(a)		870,100
	6,667	Flex Ltd.^(a)		1,080,521
	549	Lumentum Holdings, Inc.^(a)		471,075
	1,902	Seagate Technology Holdings PLC		1,835,430
				10,103,401

ADR	- American Depositary Receipt

LTD	- Limited Company

N.V.	- Naamioze Vennootschap

PLC	- Public Limited Company

Shares			Fair Value
		COMMON STOCKS — 93.7%
		AEROSPACE & DEFENSE - 1.1%
	64,205	Axon Enterprise, Inc.^(a)	$	35,993,965

		BIOTECH & PHARMA - 12.3%
	75,482	Argenx S.E. - ADR^(a)		70,029,935
	257,138	Axsome Therapeutics, Inc.^(a)		62,939,668
	1,344,376	Collegium Pharmaceutical, Inc.^(a)		48,666,411
	175,194	Insmed, Inc.^(a)		18,679,184
	709,135	Mirum Pharmaceuticals, Inc.^(a)		83,018,435
	1,460,906	Scholar Rock Holding Corporation^(a)		80,349,830
	460,684	TransMedics Group, Inc.^(a)		30,598,631
	514,957	Vaxcyte, Inc.^(a)		29,934,451
				424,216,545
		COMMERCIAL SUPPORT SERVICES - 0.7%
	150,479	Waste Connections, Inc.		25,083,344

		CONSTRUCTION MATERIALS - 1.4%
	166,555	Vulcan Materials Company		49,135,391

		E-COMMERCE DISCRETIONARY - 0.8%
	1,388,791	Chewy, Inc., Class A^(a)		27,289,743

		ELECTRIC UTILITIES - 2.1%
	51,151	Talen Energy Corporation^(a)		19,655,283
	333,361	Vistra Corporation		52,881,056
				72,536,339
		ELECTRICAL EQUIPMENT - 9.1%
	135,153	Bloom Energy Corporation, Class A^(a)		40,910,813
	35,355	GE Vernova, Inc.		41,537,175
	292,356	Generac Holdings, Inc.^(a)		85,604,760
	48,962	Rockwell Automation, Inc.		24,240,107
	189,717	Trane Technologies PLC		93,181,402
	86,292	Vertiv Holdings Company, Class A		28,892,287
				314,366,544

Shares			Fair Value
		COMMON STOCKS — 93.7% (Continued)
		ENGINEERING & CONSTRUCTION - 3.2%
	11,686	Comfort Systems USA, Inc.	$	23,161,068
	479,463	Frontdoor, Inc.^(a)		37,201,534
	67,645	Quanta Services, Inc.		48,707,106
				109,069,708
		GAS & WATER UTILITIES - 0.7%
	535,784	NiSource, Inc.		25,476,529

		HEALTH CARE FACILITIES & SERVICES - 0.5%
	266,042	GeneDx Holdings Corporation^(a)		18,263,783

		HOME CONSTRUCTION - 1.0%
	211,004	DR Horton, Inc.		34,368,332

		INDUSTRIAL INTERMEDIATE PROD - 5.9%
	2,095,492	Xometry, Inc., Class A^(a)		202,256,888

		INDUSTRIAL SUPPORT SERVICES - 5.3%
	690,508	Fastenal Company		33,165,099
	519,570	RB Global, Inc.		60,503,927
	79,189	United Rentals, Inc.		89,712,426
				183,381,452
		MACHINERY - 0.4%
	108,663	Xylem Inc		12,845,053

		MEDICAL EQUIPMENT & DEVICES - 11.4%
	3,983,917	Beta Bionics, Inc.^(a),(b)		62,427,979
	219,392	Dexcom, Inc.^(a)		14,776,051
	1,265,290	Guardant Health, Inc.^(a)		189,831,459
	57,024	Intuitive Surgical, Inc.^(a)		22,677,304
	582,472	iRhythm Technologies, Inc.^(a)		69,285,045
	25,043	Mettler-Toledo International, Inc.^(a)		31,992,683
				390,990,521
		OIL & GAS PRODUCERS - 2.4%
	162,750	DT Midstream, Inc.		23,881,935

Shares			Fair Value
		SHORT-TERM INVESTMENTS — 0.2%
		MONEY MARKET FUNDS - 0.2%
	5,656,050	Fidelity Money Market Government Portfolio, Class I, 3.52%^(g)	$	5,656,050
	1,311,079	First American Government Obligations Fund, Class U, 3.58%^(g)		1,311,079
		TOTAL SHORT-TERM INVESTMENTS (Cost $6,967,129)		6,967,129

		TOTAL INVESTMENTS - 95.1% (Cost $1,468,363,990)	$	3,268,645,351
		OTHER ASSETS IN EXCESS OF LIABILITIES - 4.9%		170,002,476
		NET ASSETS - 100.0%	$	3,438,647,827

ADR	- American Depositary Receipt

CVR	- Contingent Value Rights

LTD	- Limited Company

N.V.	- Naamioze Vennootschap

PLC	- Public Limited Company

S.E.	- Societas Europaea

Shares			Fair Value
		COMMON STOCKS — 94.0%
		BIOTECH & PHARMA - 77.0%
	394,782	Abivax S.A. - ADR^(a)	$	52,608,649
	2,220,000	Achieve Life Sciences, Inc.^(a)		14,496,600
	566,037	Adlai Nortye Ltd. - ADR^(a),(b),(c)		6,509,426
	718,747	Adlai Nortye Ltd. - ADR^(a)		8,265,591
	507,000	Aktis Oncology, Inc.^(a)		16,340,610
	1,324,994	Amylyx Pharmaceuticals, Inc.^(a)		23,796,892
	260,000	Apogee Therapeutics, Inc.^(a)		34,509,800
	49,193	Argenx S.E. - ADR^(a)		45,639,790
	370,000	Arrowhead Pharmaceuticals, Inc.^(a)		30,158,700
	100,000	Avalyn Pharma, Inc.^(a)		3,292,000
	1,275,486	Avalyn Pharma, Inc.^(a),(b),(c)		41,988,999
	56,024	Axsome Therapeutics, Inc.^(a)		13,712,994
	328,624	BeLite Bio Inc^(a)		50,603,167
	62,205	Belite Bio, Inc. - ADR^(a)		9,578,637
	437,130	Bridgebio Pharma, Inc.^(a)		32,557,442
	130,013	Bright Minds Biosciences, Inc.^(a)		9,126,913
	1,037,000	Celldex Therapeutics, Inc.^(a)		38,586,770
	366,397	CG oncology, Inc.^(a)		26,032,507
	564,028	Cytokinetics, Inc.^(a)		48,049,545
	710,000	Definium Therapeutics, Inc.^(a)		33,398,400
	225,261	Dianthus Therapeutics, Inc.^(a)		21,958,442
	395,235	Disc Medicine, Inc.^(a)		28,907,488
	269,010	Evommune, Inc.^(a),(b),(c)		3,575,143
	940,119	Evommune, Inc.^(a)		12,494,182
	1,245,583	EyePoint Pharmaceuticals, Inc.^(a)		17,811,837
	65,000	Ideaya Biosciences, Inc.^(a)		2,422,550
	3,891,019	Immix Biopharma, Inc.^(a),(e)		40,116,406
	61,545	Inhibrx Biosciences, Inc.^(a)		5,831,389
	4,277,071	InMed Pharmaceuticals Inc. ^{(a),(b),(c),(d)}		5,096,130
	403,424	Insmed, Inc.^(a)		43,013,067
	575,000	Ionis Pharmaceuticals, Inc.^(a)		45,591,750
	596,411	Kardigan, Inc. ^(a),(b),(c)		14,224,402
	300,000	Kardigan, Inc.^(a)		7,155,000
	503,000	Kymera Therapeutics, Inc.^(a)		57,679,010

Shares			Fair Value
		COMMON STOCKS — 94.0% (Continued)
		BIOTECH & PHARMA - 77.0% (Continued)
	873,492	MBX Biosciences, Inc.^(a)	$	48,216,758
	530,258	Mirum Pharmaceuticals, Inc.^(a)		62,077,304
	1,297,893	Nurix Therapeutics, Inc.^(a)		31,486,884
	951,433	ORIC Pharmaceuticals, Inc.^(a)		10,304,019
	240,000	Oruka Therapeutics, Inc.^(a)		22,840,800
	9,877,984	Ovid therapeutics, Inc.^(a),(e)		26,571,777
	1,934,257	Ovid therapeutics, Inc.^(a)		5,203,151
	231,484	Palvella Therapeutics, Inc.^(a)		35,375,385
	38,307	Praxis Precision Medicines, Inc.^(a)		12,824,801
	842,106	Relmada Therapeutics, Inc.^(a),(b),(c)		5,827,374
	1,016,310	Relmada Therapeutics, Inc.^(a)		7,032,865
	225,218	Revolution Medicines, Inc.^(a)		42,178,827
	632,699	Scholar Rock Holding Corporation^(a)		34,798,445
	474,969	Sionna Therapeutics, Inc.^(a)		20,893,886
	200,000	Spyre Therapeutics, Inc.^(a)		17,756,000
	585,262	Sutro Biopharma, Inc.^(a)		19,430,698
	400,000	Tango Therapeutics, Inc.^(a)		12,504,000
	82,628	TransMedics Group, Inc.^(a)		5,488,152
	2,660,000	Trevi Therapeutics, Inc.^(a)		49,609,000
	26,569	United Therapeutics Corporation^(a)		14,395,881
	827,521	Vaxcyte, Inc.^(a)		48,103,796
				1,378,050,031
		HEALTH CARE FACILITIES & SERVICES - 0.8%
	616,720	Kailera Therapeutics, Inc.^(a)		13,586,341

		MEDICAL EQUIPMENT & DEVICES - 14.2%
	2,052,176	Beta Bionics, Inc.^(a)		32,157,598
	195,580	Celcuity, Inc.^(a)		20,461,579
	252,611	Dexcom, Inc.^(a)		17,013,351
	142,692	Glaukos Corporation^(a)		19,942,634
	640,321	Guardant Health, Inc.^(a)		96,067,360
	277,739	iRhythm Technologies, Inc.^(a)		33,037,054
	1,368,136	Kestra Medical Technologies, Inc.^(a)		34,805,380
				253,484,956

			Expiration	Exercise
Shares			Date	Price		Fair Value
		WARRANT — 0.2%
		BIOTECH & PHARMA - 0.2%
	114,809	Biosplice Therapeutics, Inc. Series C Warrant^{(a),(b),(c),(d),(f)}	09/12/2027	$	0.9800		—
	1,457,473	Goldfinch Bio Inc Series B Warrant^{(a),(b),(c),(d),(e),(f)}	02/18/2036		1.1800		—
	2,142,500	Ovid Therapeutics, Inc Series B Warrant^{(a),(b),(c),(d),(f)}	10/06/2030		1.4000		3,535,125
							3,535,125

		TOTAL WARRANT (Cost $–)					3,535,125

Shares						Fair Value
		SHORT-TERM INVESTMENTS — 1.1%
		MONEY MARKET FUNDS – 1.1%
	3,693,650	Fidelity Money Market Government Portfolio, Class I, 3.52%^(h)					3,693,650
	15,445,721	First American Government Obligations Fund, Class U, 3.58%^(h)					15,445,721
		TOTAL SHORT-TERM INVESTMENTS (Cost $19,139,371)					19,139,371

		TOTAL INVESTMENTS – 96.9% (Cost $ 1,133,582,135)				$	1,733,713,060
		OTHER ASSETS IN EXCESS OF LIABILITIES - 3.1%					55,667,196
		NET ASSETS - 100.0%				$	1,789,380,256

ADR	- American Depositary Receipt

CVR	- Contingent Value Rights

PIK	- Payment in Kind

S.A.	- Societe Anonyme

S.E.	- Societas Europaea

Shares			Fair Value
		COMMON STOCKS — 97.1%
		BANKING - 1.6%
	40,461	Fifth Third Bancorp	$	2,280,787
	59,832	Huntington Bancshares Inc		1,060,821
				3,341,608
		BIOTECH & PHARMA - 6.6%
	5,762	Amgen, Inc.		2,086,535
	2,514	Eli Lilly & Company		3,015,367
	148,912	Royalty Pharma plc, Class A		8,349,496
				13,451,398
		CHEMICALS - 5.2%
	16,907	Linde PLC		8,773,719
	5,641	Sherwin-Williams Company (The)		1,942,309
				10,716,028
		CONTAINERS & PACKAGING - 0.6%
	30,275	International Paper Company		1,153,478

		ELECTRIC UTILITIES - 7.6%
	16,806	Constellation Energy Corporation		4,174,107
	27,623	Entergy Corporation		3,172,778
	43,373	NextEra Energy, Inc.		3,806,848
	35,123	Southern Company (The)		3,361,622
	2,382	Talen Energy Corporation^(a)		915,307
				15,430,662
		ELECTRICAL EQUIPMENT - 10.4%
	10,485	GE Vernova, Inc.		12,318,407
	18,211	Trane Technologies PLC		8,944,515
				21,262,922
		HOME CONSTRUCTION - 1.2%
	15,145	DR Horton, Inc.		2,466,818

		INDUSTRIAL SUPPORT SERVICES - 2.5%
	4,532	United Rentals, Inc.		5,134,257

Shares			Fair Value
		COMMON STOCKS — 97.1% (Continued)
		INSTITUTIONAL FINANCIAL SERVICES - 1.2%
	32,206	Nasdaq, Inc.	$	2,538,477

		MACHINERY - 1.1%
	2,038	Caterpillar, Inc.		2,170,266

		MEDICAL EQUIPMENT & DEVICES - 3.9%
	23,226	Boston Scientific Corporation^(a)		991,286
	39,251	Medtronic PLC		3,070,606
	3,111	Mettler-Toledo International, Inc.^(a)		3,974,333
				8,036,225
		OIL & GAS PRODUCERS - 2.4%
	66,599	Williams Companies, Inc. (The)		4,950,970

		RETAIL - DISCRETIONARY - 6.5%
	8,880	Ferguson Enterprises, Inc.		2,107,490
	8,655	Home Depot, Inc. (The)		3,052,445
	9,695	Lowe’s Companies, Inc.		2,137,651
	64,816	O’Reilly Automotive, Inc.^(a)		5,968,906
				13,266,492
		SEMICONDUCTORS - 25.3%
	10,169	Advanced Micro Devices, Inc.^(a)		5,907,274
	916	ASML Holding N.V. - ADR		1,822,327
	26,090	Broadcom, Inc.		9,855,498
	22,130	KLA Corporation		6,676,842
	12,765	Lam Research Corporation		5,531,457
	935	Micron Technology, Inc.		1,079,261
	943	Monolithic Power Systems, Inc.		1,303,566
	64,173	NVIDIA Corporation		12,840,376
	14,199	Taiwan Semiconductor Manufacturing Company Ltd. - ADR		6,781,016
				51,797,617
		SOFTWARE - 5.6%
	11,942	Cadence Design Systems, Inc.^(a)		4,482,071
	3,976	Intuit, Inc.		1,037,736
	1,618	MongoDB, Inc.^(a)		543,486

ARMS	Adjustable Rate Mortgages

LLC	Limited Liability Company

L.P.	Limited Partnership

H15T1Y	US Treasury Yield Curve Rate T Note Constant Maturity 1 Year

H15T5Y	US Treasury Yield Curve Rate T Note Constant Maturity 5 Year

SOFRINDX	United States SOFR Index

SOFRRATE	United States SOFR Secured Overnight Financing Rate

	Eventide		Eventide			Eventide		Eventide
	Balanced		Core Bond			Dividend		Exponential		Eventide
	Fund		Fund			Growth Fund		Technologies Fund		Gilead Fund
ASSETS
Investment securities:
Unaffiliated investments at cost	$	314,034,944	$	213,390,052		$	963,170,106	$	66,789,091	$	1,402,427,342
Affiliated investments at cost		—		—			—		—		65,936,648
Total Investments at cost		314,034,944		213,390,052			963,170,106		66,789,091		1,468,363,990
Unaffiliated investments at value	$	392,920,165	$	210,571,414		$	1,401,765,511	$	99,471,924	$	3,206,217,372
Affiliated investments at value		—		—			—		—		62,427,979
Total investments at value		392,920,165		210,571,414			1,401,765,511		99,471,924		3,268,645,351
Cash held at custodian		3,842,251		3,338,633			22,382,862		4,152,064		135,539,530
Cash held at broker		119,958		—			115,751		282,294		1,071,321
Receivable for securities sold		—		—			3,475,893		2,600,335		53,723,965
Receivable for Fund shares sold		133,673		494,271			2,134,941		49,067		1,102,006
Dividends and interest receivable		1,964,282		2,196,669			1,049,823		39,187		1,097,943
Prepaid expenses and other assets		60,825		9,335			202,237		15,283		119,508
TOTAL ASSETS		399,041,154		216,610,322			1,431,127,018		106,610,154		3,461,299,624

LIABILITIES
Payable for investments purchased		—		1,217,598			3,601,807		527,706		16,797,418
Payable for Fund shares redeemed		400,253		99,433			714,852		124,280		2,555,401
Advisory fees payable		188,020		54,640			940,982		87,595		2,622,519
Distribution (12b-1) fees payable		111,924		10,921			202,196		25,386		78,836
Payable to related parties		53,745		37,966			143,224		23,641		287,382
Accrued expenses and other liabilities		53,970		55,675			195,986		61,616		310,241
TOTAL LIABILITIES		807,912		1,476,233			5,799,047		850,224		22,651,797
NET ASSETS	$	398,233,242	$	215,134,089		$	1,425,327,971	$	105,759,930	$	3,438,647,827

Composition of Net Assets:
Paid in capital	$	317,515,486	$	232,599,936		$	986,900,909	$	103,437,573	$	1,682,672,001
Accumulated earnings (losses)		80,717,756		(17,465,847	)		438,427,062		2,322,357		1,755,975,826
NET ASSETS	$	398,233,242	$	215,134,089		$	1,425,327,971	$	105,759,930	$	3,438,647,827

				Eventide			Eventide		Eventide
	Eventide			Core Bond			Dividend		Exponential			Eventide
	Balanced			Fund			Growth Fund		Technologies Fund			Gilead Fund
INVESTMENT INCOME
Dividend income	$	2,977,790		$	—		$	17,094,238	$	157,688		$	9,764,252
Interest		8,135,626			8,103,743			668,184		152,768			4,970,805
Less: Foreign dividend withholding taxes		—			—			—		(8,976	)		(272,726	)
TOTAL INVESTMENT INCOME		11,113,416			8,103,743			17,762,422		301,480			14,462,331

EXPENSES
Investment advisory fees		2,327,672			574,487			9,014,924		889,025			28,902,794
Distribution (12b-1) fees:
Class N		32,030			76,607			152,726		30,814			586,045
Class A		105,356			5,786			175,742		21,202			825,902
Class C		172,897			6,043			277,340		20,031			1,379,685
Shareholder servicing fees		347,218			217,686			1,468,449		126,346			2,676,662
Financial administration/fund accounting fees		146,020			83,746			356,368		50,824			818,752
Legal administration/management services fees		79,980			34,753			254,400		18,768			605,244
Registration fees		73,000			51,100			120,283		69,350			118,625
Transfer agent fees		41,098			19,944			87,255		23,602			225,868
Printing and postage expenses		61,249			28,253			139,613		31,549			246,145
Custodian fees		20,560			9,184			59,255		8,106			160,316
Legal fees		20,875			19,727			16,752		19,426			20,827
Compliance officer fees		18,780			13,272			37,572		9,149			79,905
Trustees fees and expenses		16,630			16,631			16,631		16,631			16,630
Audit fees		18,189			11,023			36,816		12,943			77,249
Insurance expense		12,775			3,650			20,075		3,650			109,500
Other expenses		3,980			3,789			4,438		3,974			6,040
TOTAL EXPENSES		3,498,309			1,175,681			12,238,639		1,355,390			36,856,189
Less: Fees waived/reimbursed by the Adviser		(6,574	)		(250,074	)		—		(41,200	)		—
Plus: Recapture of fees previously waived		—			—			104,555		—			—
NET EXPENSES		3,491,735			925,607			12,343,194		1,314,190			36,856,189

NET INVESTMENT INCOME (LOSS)		7,621,681			7,178,136			5,419,228		(1,012,710	)		(22,393,858	)

REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS
Net realized gain from:
Unaffiliated investments		7,380,540			432,743			14,162,174		17,869,673			39,177,700
Affiliated investments (See Note 5)		—			—			—		—			—
Redemptions in-kind		1,440,168			—			12,525,080		10,584,398			404,187,098
Securities sold short		—			—			—		(553,772	)		3,119,825
Foreign currency transactions		—			—			—		—			2,522
Net realized gain:		8,820,708			432,743			26,687,254		27,900,299			446,487,145

Net change in unrealized appreciation (depreciation) on:
Unaffiliated investments		36,515,794			(816,268	)		231,468,531		3,662,036			590,316,776
Affiliated investments (See Note 5)		—			—			—		—			3,003,288
Net change in unrealized appreciation (depreciation):		36,515,794			(816,268	)		231,468,531		3,662,036			593,320,064

NET REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS		45,336,502			(383,525	)		258,155,785		31,562,335			1,039,807,209

NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	52,958,183		$	6,794,611		$	263,575,013	$	30,549,625		$	1,017,413,351

	For the			For the
	Year Ended			Year Ended
	June 30, 2026			June 30, 2025
FROM OPERATIONS
Net investment income	$	7,621,681		$	7,277,439
Net realized gain from investments and in-kind redemptions		8,820,708			23,798,429
Net change in unrealized appreciation		36,515,794			273,040
Net increase in net assets resulting from operations		52,958,183			31,348,908

DISTRIBUTIONS TO SHAREHOLDERS
From Accumulated Earnings
Class N		(937,807	)		(343,693	)
Class A		(2,463,608	)		(592,586	)
Class C		(881,420	)		(171,720	)
Class I		(19,019,223	)		(6,417,037	)
Total distributions to shareholders		(23,302,058	)		(7,525,036	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		2,866,807			5,425,454
Class A		13,073,629			10,050,801
Class C		2,996,733			3,676,253
Class I		64,745,412			79,882,967
Net asset value of shares issued in reinvestment of distributions:
Class N		871,199			320,908
Class A		2,315,591			541,839
Class C		843,398			161,394
Class I		17,913,877			5,855,202
Payments for shares redeemed:
Class N		(7,540,356	)		(10,887,263	)
Class A		(7,506,157	)		(5,652,475	)
Class C		(3,924,015	)		(4,011,035	)
Class I		(105,121,436	)		(101,665,264	)
Net decrease in net assets from shares of beneficial interest		(18,465,318	)		(16,301,219	)

TOTAL INCREASE IN NET ASSETS		11,190,807			7,522,653

NET ASSETS
Beginning of Year		387,042,435			379,519,782
End of Year	$	398,233,242		$	387,042,435

Eventide Balanced Fund
Assets
Security Classifications	Level 1		Level 2		Level 3		Totals
Common Stocks ^(a)	$	216,540,050	$	—	$	—	$	216,540,050
Asset Backed Securities ^(a)		—		4,181,988		—		4,181,988
Collateralized Mortgage Obligations ^(a)		—		1,903,224		—		1,903,224
Corporate Bonds ^(a)		—		82,400,434		—		82,400,434
Municipal Bonds ^(a)		—		16,524,880		—		16,524,880
U.S. Government & Agencies ^(a)		—		71,248,482		—		71,248,482
Short-Term Investments		121,107		—		—		121,107
Total	$	216,661,157	$	176,259,008	$	—	$	392,920,165